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CHAPTER 1. General Introduction 
 
Dissertation Organization  
 This dissertation follows the new format of thesis organization in which manuscripts are included as 
the main component of the dissertation. The first chapter encompasses the general introduction and literature 
review providing detailed experiments by other research groups with the intent to introduce the reader to topics 
reported on in the dissertation. Since the thesis is one complete document, the manuscripts have been formatted 
and included as chapters two, three, and four. These manuscripts will be/are in the process of submission for 
publication. The entire document is tied together in the last chapter discussing the results of all three 
manuscripts.  
 
Literature Review 
 
Inflammatory Bowel Disease  
 The gastrointestinal (GI) tract is commonly thought of as the organ with the largest surface area (100 
m2) in the body to digest and absorb 500 kg of food per year, however a function that perhaps is less thought of 
is its role as the physical interface between the immune system and the antigens of daily life. The GI tract is 
colonized with a plethora of beneficial commensal bacteria. This is a beneficial relationship because the 
microbiota live in a nutrient rich environment consisting of ingested food and assist in the breakdown of 
compounds, like cellulose for which humans do not have digestive enzymes. However, the GI tract is also 
exposed to environmental dangers like pathogenic bacteria that have varying capabilities to invade and to 
colonize the intestinal mucosa. The constant bombardment of food and microbes creates the necessity for a 
delicate balance between defending against pathogens while maintaining the beneficial relationship of 
commensal bacteria. An imbalance or defect in multiple areas of innate or adaptive immunity may result in 
chronic inflammatory bowel disease. 
 Gastrointestinal diseases have a significant economic impact costing the U.S. between 1.8 to 2.6 billion 
dollars per year (1). Inflammatory bowel disease (IBD) is a chronic inflammation of the GI tract. The exact 
etiology of IBD is unknown, but is thought to be multi-factorial. Previous studies indicate that genetics and 
environment strongly associate with the development of an aberrant immune response resulting in IBD (2-4). 
The main diseases commonly associated with IBD are Crohn’s disease (CD) and ulcerative colitis (UC). 
Crohn’s disease is a transmural inflammation that can manifest in any area of the GI tract; however, CD 
typically affects the distal ileum (5). Lesions are usually multifocal and are associated with an increased 
infiltration of macrophages that contribute to granuloma development. Some CD patients also experience 
fistulas or obstructing strictures (6). Ulcerative colitis lesions are superficial and tend to only affect the colon. 
These lesions are associated with neutrophil infiltration into the lamina propria and a depletion of goblet cell 
mucin is also observed histologically. Aphthous or linear ulcers form over Peyer’s patches and lymphoid 
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nodules and are characterized by purulent secretions which cause the colon to frequently empty, resulting in 
diarrhea. Other symptoms that patients with CD or UC may experience include vomiting, crampy abdominal 
pain, rectal bleeding, and weight loss. One in 300 people experience these symptoms, but typically not until the 
second to third decade of their life and 30% of IBD cases are diagnosed during childhood (7). Incidence rates 
and prevalence of UC or CD are highest in Europe and the US, while the lowest rates are observed in South 
America, southeast Asia, Africa, and Australia (8). Therefore, it has been hypothesized that environmental 
influences such as diet, improved sanitation, and pollution affect the incidence of IBD in western societies 
causing many to speculate that the hygiene hypothesis may contribute to disease development (9, 10). Although 
IBD can affect males and females equally, the Jewish population has a greater susceptibility to CD than other 
ethnic groups and they are three to five times more likely to get UC (8).  
Pathogenesis  
 IBD is a multi-genetic disease in mice and humans that is hypothesized to result from a defect in 
multiple components of the immune response in immune competent individuals (11). For example, a defect in 
innate immunity, toll-like receptors (TLRs) results in priming of CD4 T cells resulting in IBD (12). A 
deficiency in T regulatory cells or an excessive amount of effector T cells also results in IBD (13-20). Although 
an idiopathic disease, the most agreed upon hypothesis contributing to IBD is that an inappropriate immune 
response develops in reaction to microbial antigens due to persistent infection, dysbiosis, and/or genetic defects 
that affect microbial clearance and epithelial barrier function (21, 22). The adaptive immune response that 
develops to the microbial invasion is inadequate, resulting in excessive recruitment of effector cells and 
dysregulation of local immunity, rather than alleviation or elimination of the underlying cause of disease.  
Importance of Resident microbiota/Environment 
The importance of the commensal microbiota in the pathogenesis of IBD is apparent from many studies. Biopsy 
samples from CD patients have a greater concentration and thicker layer of bacteria associated with the mucosal 
epithelium compared to healthy individuals (23, 24). Another example of the significance of the microbiota in 
relation to IBD is the amelioration of symptoms in patients treated with broad spectrum antibiotics like 
metronidazole or ciprofloxacin (25-27). Probiotics are living bacteria that have been shown to promote the 
health of the host by enhancing the epithelial barrier and by altering proinflammatory cytokine expression of 
epithelial cells (28, 29). Cocktails containing species of Bifidobacterium, Streptococus and/or Lactobacillus 
prevent the relapse of UC patients (30). However, probiotics have been shown to have the most benefit in cases 
of pouchitis (22). Furthermore, 50% of CD patients have positive serological responses to bacterial components 
including flagellin, OmpC (outer membrane porin C of E. coli), I2 (microbial sequence homolog in 
Pseudomonas fluorescens of the tetR bacterial transcription factor family), or Saccharomyces cerevisiae (31).  
Research on identical twins show that only 50% that share susceptible genes for IBD develop Crohn’s disease, 
indicating that genetics are not the sole reason for IBD development and implicating a significant role for 
environmental factors in the development of IBD (32). Laboratory research has also demonstrated the 
significance of the enteric flora to the development or onset of colitis (21, 33-38). There are numerous animal 
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models of IBD including genetic knockouts, transgenic, spontaneously occurring, or chemically induced models 
of colitis. Although dissimilar, they share a common theme: depletion of the enteric flora results in 
elimination/amelioration of clinical signs of disease. For example, IL10-/- mice spontaneously develop clinical 
signs of colitis when housed in conventional conditions; however, in a germ free environment, IBD does not 
occur, unless the mice are reconstituted with a bacterial flora (34). Others have reasoned for the importance of 
the enteric flora by developing IBD hypotheses based on various premises including persistent infection, 
dysbiosis, defective clearance of microbes, and defective epithelial barrier as discussed below (22). 
Persistent infection.  
Chronic infection with pathogens has been hypothesized to predispose patients to IBD. One of the 
most notorious bacterial agents implicated in causing IBD is Mycobacterium avium subspecies paratuberculosis 
because it causes colitis in cattle (Johne’s disease). Johne’s disease is a chronic wasting intestinal disease that 
occurs in wild and domesticated animals with granulomatous lesions primarily in the small intestine. M. avium 
was first cultured from granulomas of CD patients in the 1980’s (39). Other reports have identified M. avium in 
blood and other body fluids from CD patients (40, 41). Serum antibody levels to M. avium are elevated in CD 
patients indicating presence of this organism (42). A recent study reported that M. avium infections exacerbates 
colitis in IL10-/- mice (43). Mucosal CD4+ T cells from IL10-/- mice administered M. avium 
subsp.paratuberculosis proliferated greater and secreted elevated antigen specific IFN-γ that CD4+ from IL10-/- 
mice alone. Arguments against M. avium being the causative agent of IBD are that comparisons between the 
clinical signs and pathological responses of Johne’s and Crohn’s disease are different (44). CD is segmental in 
nature and symptoms include ulcerations, bleeding, stricturing, adhesions, perforations and abscesses, whereas 
these are not clinical signs associated with Johne’s disease (45). Also, there have been no documented cases of 
M. avium being transmitted from infected cattle to humans (46). However, human M. avium has been 
transferred into goats and one animal was shown to have intestinal inflammation 5 months postinfection. Acid-
fast bacilli were not isolated back from the intestine, but a single organism was detected in the mesenteric 
lymph node (39). Although this may fulfill Koch’s third postulate, more research needs to be performed to 
confirm if M. avium causes CD. In a five year clinical trial, there was no benefit or amelioration of disease 
when 130 patients with active CD were given anti-tuberculous chemotherapeutic agents (47). Other agents that 
have been implicated in IBD pathogenesis but do not have substantial data include Pseudomonas species, 
Listeria monocytogenes, Helicobacter species and measles (4, 5, 22, 48)  
Dysbiosis.  
Compared to human somatic and germ-line cells, the human microbiota outnumber human cells by ten 
fold. The enormity of this microbial community begs consideration when investigating human health and 
disease. This combined microbiome is a mutualistic relationship between our enteric flora and gastrointestinal 
tract. Humans provide the nutrient rich environment for bacteria to multiply and in exchange the bacteria assist 
in the degradation of food, metabolic activities, and also contribute to the development of the innate and 
adaptive immune systems. Because the commensal microbiota contribute to the development of the gut and 
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immune response, it is not outrageous to hypothesize that they may also contribute to the breakdown of 
intestinal health and aberrant immune response associated with IBD. One hypothesis suggests that there is an 
imbalance in the ratio of beneficial to harmful bacteria in the gastrointestinal tract of individuals with IBD. 
Examples of beneficial bacteria include Lactobacilllus species, Bifidobacterium species, selected E. coli strains 
and Streptococcus salivarius. Aggressive bacteria include Bacteroides species, Enterococcus faecalis, 
adherent/invasive or toxigenic E. coli, Eubacterium and Peptostreptococcus species, Fusobacterium varium, 
and Helicobacter species. Factors that may contribute to dysbiosis include the use of antibiotics, diet, and 
potentially the impact of refrigeration in the 20th century or the “cold chain hypothesis” (49). Antibiotic therapy 
seems a natural choice to have contributed to dysbiosis since opportunistic infections may occur following 
treatment, however, treatment only transiently changes the microbial flora and when treatment is discontinued 
the original state or composition of the microbioa returns (50). There is also evidence that diet may contribute to 
dysbiosis. Infants that were breastfed had a disparate microflora compared to formula fed infants. Breastfeeding 
increased numbers of Bifidobacteria whereas bottle fed infants had a slightly higher percentage of E. coli and 
Clostridium dificile (51). Contributions of the cold chain hypothesis to dysbiosis has received mixed reviews. 
Hugot et al hypothesize that bacteria that can survive at lower temperatures, called psychrotropic bacteria and 
may have increased due to modern refrigeration (52). Some of these bacteria include Listeria monocytogenes, 
Yersinia enterocolitica, Clostridium botulinum, and Bacillus cereus.  However, another study did not find any 
differences between CD patients and controls in regards to the age at which they first experienced refrigerated 
foods (53). Other factors can also influence the composition of the intestinal flora including geography, illness, 
emotional stress, and age (54-58). Compared to healthy humans, patients with CD have a decrease in microbial 
diversity including increased numbers of Enterobacteriaceae and decreased Firmicutes (including Clostridium 
XIV) (59). Swidsinski’s and colleagues reported that the diversity of adherent bacteria in IBD patient’s was 
very low and the main adherent bacteria in the biofilm of IBD patients was Bacteroides fragilis (60). Effects of 
an imbalance in harmful vs beneficial bacteria include the contribution of metabolic constituents to epithelial 
health. Butyrate, an energy substrate for epithelial cells, is produced by various species of Clostridium and 
Bacteroides. Therefore, decreased members of these genera may negative impact epithelial health and integrity. 
Another example of the importance of flora to intestinal health is shown by the fact that germfree mice renew 
their epithelium at a slower rate than flora-bearing mice (61). This thought has lead to probiotic and prebiotic 
studies that increase the beneficial bacteria like Lactobacillus species or beneficial nonabsorbed carbohydrates 
like fructose that promote the growth of beneficial bacteria like Bifidobacterium. Commensal bacteria 
contribute to the innate immune response by altering the expression of angiogenin-4, a bacteriocidal protein that 
kills Gram-negative bacteria. Contributions to adaptive immunity include the expansion of germinal centers and 
diversity of antibody repertoire and increasing production of IgA (62). 
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Genetic defects 
IBD is a multigenic disease with a diversity of genes implicated in its pathogenesis. However, when 
comparing the penetrance of IBD for monozygous twins, they only have a 20-50% chance of developing CD, 
and only a 6-14% chance of developing UC (32). While important, these observations indicate that genetics are 
not the sole indicator or predictor for IBD development and that environmental triggers are likely to have an 
impact. Although abundant, the genetic aberrations contributing to IBD progression are categorized into 3 main 
classes: defective clearance of microbial organisms, aberrations in mucosal barrier and aberrant 
activation/regulation of immunity.  
Defective Clearance of microbial organisms 
NOD2/CARD15 (nucleotide-binding oligomerization domain 2/caspase-recruitment domain 15) 
located on chromosome 6, is a cytosolic receptor that recognizes bacterial components and can initiate innate 
immune responses. NOD2 mutations or polymorphisms are strongly correlated with 25 to 35 % of Crohn’s 
disease cases but not with ulcerative colitis (21). Monocytes, DCs, and epithelial cells express this intracellular 
receptor. Activation of NOD2 through binding of muramyl dipeptide (MDP), a product of peptidoglycan 
degradation, activates NF-kB or the mitogen–activated protein kinase (MAPK) pathway (63). Mice that are 
deficient for NOD2 do not spontaneously develop IBD; however, they are susceptible to bacterial infections 
(64). When intragastrically gavaged with L. monocytogenes, NOD2-/- mice had greater numbers of bacteria in 
the liver and spleen compared with wildtype mice. This lack of innate protection was attributed to a defect in 
NF-kB activation in Paneth cells, thus decreasing production of antimicrobial peptides (64). Another group 
developed mice with a NOD2 knockin (KI) mutation at position 2939 (similar to the human NOD2 mutation 
3020) (65). NOD2 KI mice were more susceptible to DSS-induced colitis compared to wildtype mice and were 
characterized by greater NF-kB activity. When macrophages were stimulated with MDP, they had greater NF-
kB activation and IL-1ß secretion than controls. This model may be more consistent with human CD since 
patients have elevated NF-kB activity. Since MDP can also be recognized by TLR2 and activate NF-kB through 
MyD88, it was hypothesized by Watanabe et al that TLR2 and NOD2 signaling may be linked (66). Recent 
studies showed that pretreating mice with MDP, thus upregulating NOD2 expression, protected them from DSS 
or TNBS-induced colitis (66). This protection was mediated through suppression of multiple TLR pathways 
including TLR2, 3, 4, 5, and 9 and required IRF4. Furthermore, the ability of MDP pretreatment to protect mice 
from DSS-induced colitis was lost when NOD2 knockout mice were used in these studies (66). NOD2 has 
recently been linked with adaptive immunity in the induction of IL-17 cells from T cells. Van Beelen et al 
(2007) showed that NOD2 activation by peptidoglycan stimulated human DCs to secrete IL-1ß and IL-23. 
These activated DCs induced the production of IL-17 by memory T cells (67). Likewise, DCs harvested from 
human CD patients having mutations in NOD2 that were primed with MDP and Pam3CSK4 and incubated with 
T cells were unable to induce production of IL-17 compared to NOD2 sufficient DCs. Cumulative results 
indicate that aberrant NOD2 expression results in susceptibility to IBD (68).  
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Another manifestation of mutations in NOD2 is Blau syndrome, a rare disorder characterized by skin 
rashes, arthritis, and/or uveitis (69). Indicating that NOD2 mutations are not the solitary reason behind CD 
development, but may factor into the understanding of the etiology. NEMO (Ikb kinase-γ) is a regulator of NF-
kB activity and when this gene is knocked out in intestinal epithelial cells mice develop severe pancolitis (70). 
Other characteristics include decreased secretion of antimicrobial peptides and increased bacterial translocation 
indicating that NEMO is essential to gut barrier health and integrity. Other genes associated with IBD that 
function to clear microbes are related with autophagy. ATG16L1 (Autophagy-related 16-like gene)is expressed 
in intestinal epithelium, APCs, CD4/8 T cells, B1 cells, and memory B cells. ATG16L1 and IRGM (immunity-
related guanosine triphosphatase-human homologue of mouse Irgm/Lrg47) are associated with increased risk 
for Crohn’s disease (71-73).   
Defective barrier 
Genes that contribute to defective epithelial barrier function have also been implicated in the 
susceptibility to IBD. DLG5 encodes an epithelial scaffolding protein and a single-nucleotide polymorphism in 
DLG5 has been associated with individuals who also have the risk-associated NOD2/CARD15 alleles and 
Crohn’s disease (74). The multidrug resistance gene (MDR1) encodes P-glycoprotein 170, an efflux drug 
transporter, and deletion of this gene results in colitis in mice (21, 75). Although MDR1a -/- mice develop a 
spontaneous colitis, research from a recent Dutch study indicated that there is no association between the human 
equivalent polymorphism, (exon 26, C3435T) and IBD (76). Prostaglandin receptor EP4 (PTGER4) is 
expressed by intestinal epithelial cells and regulates barrier function. Polymorphisms in EP4 have also been 
associated with CD in a recent genome-wide association study (77). Other genes associated with altered 
epithelial barrier functions include Gai2, Muc2, and N-cadherin. The α subunit of the Gi2 protein (on 
lymphocytes, APCs, gastrointestinal epithelial cells and other cell types) regulates adenylate cyclase activity 
and facilitates Th1 mediated colitis in Gi2a deficient mice. Mucus is an important barrier protecting the 
epithelium from luminal contents and Muc2 is a goblet cell-derived secretory mucin. Muc2 is downregulated in 
CD patients (78) and Muc2-/- mice are deficient in goblet cells and develop spontaneous colitis (79). Mice that 
are transgenic/chimeric expressing a dominant negative mutant of the cell adhesion molecule N-cadherin in 
intestinal epithelial cells develop chronic colitis characterized by a breach in epithelial permeability (80).  
Aberrant activation/regulation of immunity.  
Dysregulated immune responses are thought to contribute to IBD development and it is hypothesized that 
aberrant immune responses arise as a result of a defect in one or more of the following mechanisms; epithelial 
barrier & health, APC sampling (antigen presentation), regulation of innate/adaptive immunity, and/or 
excessive generation of effector T cells (22). Aside from the mucus layer, epithelial cells provide the first line of 
defense as a physical shield against the plethora of antigens in the gut lumen, a chemical barrier by the secretion 
of antimicrobial peptides by Paneth cells, and an immunological shield, engaging innate receptors to microbial 
ligands. In addition to the role of the epithelium in clearance of bacteria and permeability mentioned above, 
another important role is the recognition of microbial components through innate receptors. Innate mechanisms 
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that have been implicated in driving IBD include TLRs, NOD2, and pyrin-domain containing proteins that 
recognize components of bacterial cells to initiate secretion of downstream inflammatory cytokines (81). A 
simplistic form of innate immunity is the recognition of structures with repeated patterns. One class of pattern 
recognition receptors (PRRs) are TLRs, transmembrane proteins that recognize bacterial products and viral 
nucleic acids. Although the elucidation of TLRs is not complete, they aid in defense on epithelial cells and 
APCs by inducing antimicrobial peptides, chemokines, and cytokines through NF-kB activation (82). There are 
prophylatic effects of TLR agonists in murine colitis models, but mutations in these receptors can have 
detrimental effects as well (83). For example, TLR2 -/-, TLR4-/-, TLR9-/- and MyD88-/- mice are susceptible to 
DSS-induced colitis. Mice that have TLR deficiencies and leaky epithelia develop chronic inflammation 
characterized by excessive infiltration of CD4+ T cells. NF-kB activation mediated through TLR signaling is 
beneficial to epithelial homeostasis, but exacerbation can be detrimental. For example, Deletion of IkB kinase γ 
(NEMO) resulted in spontaneous colitis (70). The location of the TLRs and downstream signals can also result 
in differential immunological effects. Stimulation of TLR9 by synthetic DNA on the basolateral side of the 
epithelium activated NF-kB, whereas apical stimulation blocked NF-kB signaling due to inhibiting the break 
down of ubiquinated IkBα (84). Peroxisome proliferative-activated receptor g (PPARγ) is an intracellular 
receptor that inhibits NF-kB activation and is highly expressed in adipocytes, macrophages, T and B cells and 
colonic epithelial cells (85). Polymorphisms in the PPARγ  gene have been linked to increased susceptibility to 
ileitis development in the SAMP1/YitFC mouse model of spontaneous colitis (86). Defective PPARγ  activity 
has also been linked to UC in that downregulation of PPARγ  expression in colonic epithelium is observed (87, 
88).  
APC sampling.  
When most strains of mice that are often used as animal models of IBD are housed under germfree 
conditions, they do not develop clinical signs of colitis (37, 38, 89, 90). However, if they are reared under SPF 
or conventional housing conditions, they develop severe colitis. Therefore, the presence of an enteric flora plays 
a critical role in the development and severity of IBD. In this regard, it is reasonable to hypothesize that a defect 
in sampling (i.e., antigen processing and presentation) of antigens derived from the microbiota may predispose 
to IBD. There are three main routes for the bacterial antigens to be sampled and presented to the immune 
system. The most studied pathway is entry of the microorganism through M cells overlying Peyer’s patches. M 
cells are polarized epithelial cells specialized for antigen transport that phenotypically differ from other 
epithelial cells located in the follicular associated epithelium (FAE). The apical membrane has no brush border, 
but microdomains instead to facilitate transcytosis. The basolateral membrane is deeply invaginated to form an 
unusual pocket (91). This pocket is full of T and B cells and macrophages and shortens the distance that the 
transcytosed antigen in the vesicle has to travel to be phagocytosed and presented to lymphocytes (91, 92).  
The second method of APC sampling has been shown by Rescigno et al to be mediated by immature DCs 
extending their dendrites between and beyond the apical surface of epithelial cells to sample luminal bacteria 
while secreting tight junction proteins to preserve epithelial integrity (93). The third method to sample bacteria 
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is by the use of neonatal Fc receptors (FcRn). FcRn functions to transport IgG in the milk across the intestinal 
epithelium and into the bloodstream which serves to maintain serum IgG levels (94, 95). Recently, basolaterally 
expressed FcRn was shown to transport IgG from the lamina propria through epithelial cells and to the lumen to 
bind bacterial antigens. Following capture of antigens, the FcRn transports the package back to the lamina 
propria to be phagocytosed by DCs, and processed for antigen presentation to T cells (96, 97). This leads to 
activation and differentiation of CD4+ T cells into Th1 effectors to kill the invading bacteria or Th2 effectors to 
aid in differentiation of B cells into plasma cells that secrete antigen-specific IgG. Because bacterial antigen 
sampling is the initial phase in development of aberrant bacterial-specific T cells, these pathways may need to 
be studied in more depth. Recently some studies have shed light on how the second sampling pathway may be 
manipulated to cause or ameliorate IBD. Dendritic cells that were cultured in the presence of vasoactive 
intestinal peptide (VIP) secreted IL-10 and induced regulatory T cell development (secreted IL-10 and TGF-ß). 
Injection of VIP-stimulated DCs ameliorated TNBS induced colitis as shown by reduced gross and histological 
scores, reduced weight loss and decreased production of inflammatory cytokines and chemokines (98).  
DCs have also been associated with the induction of IBD. A CD11c+ F4/80+ population that secretes IL-23 has 
been implicated in granuloma formations in an experimental IBD model that was dependent upon the presence 
of an intestinal microbiota (99). Furthermore, antigen sampling aberrations have also been implicated in 
predisposing individuals to IBD. Specifically, an increased risk for the development of IBD has been linked to 
mutations in the IBD3 locus on chromosome 6p, encompassing the major histocompatibility complex (MHC). 
There are strong associations between HLA and CD or UC (2, 90). There is an inverse correlation between UC 
and CD with respect to HLA-DR2 mutations in that there is a positive association between HLA-DR2 and UC 
genes and a negative association with CD genes (48).  
Regulation of innate/adaptive immunity  
Considering the total microbial load, 1013-1014 organisms, the diversity of 1800 genera species that colonize the 
human gut, and the constant bombardment of food and environmental antigens, it is amazing that the immune 
system can enforce tolerance in the homeostatic state. IBD patients have broken tolerance shown by increased T 
cell reactivity and serum responses to bacterial antigens (31, 100, 101). Peripheral tolerance is primarily 
mediated by regulatory T cells (Tregs). Since the discovery of “suppressor T cells” in the 1970’s, research has 
advanced our knowledge tremendously (102). Regulatory CD4+ T cells are a population of lymphocytes that are 
able to suppress both innate and adaptive immunity (20, 103, 104). Suppression of harmful inflammatory 
responses is important to maintain homeostasis, however elevated Tregs in peripheral blood and tissues have 
been associated with cancers (105, 106). Likewise, a lack of or defect in Tregs is associated with autoimmune 
diseases such as rheumatoid arthritis, multiple sclerosis, EAE and IBD (107). Therefore, a balance of regulation 
and effector functions is required to maintain homeostatic conditions. T regulatory cells are categorized into 
naturally occurring and induced/adaptive Tregs. Naturally occurring Tregs develop in the thymus and make up 
5-10% of mouse peripheral T cells, however, only 1-2% of human peripheral T cells. Cell surface molecules to 
identify this population are unfortunately shared by other cell types. For example, Tregs are typically 
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characterized as CD4+CD25+GITR+CTLA4+ among others, however, CD25, GITR and CTLA4 are activation 
markers that can be upregulated on effector non-suppressive cells. The hunt for new cell surface markers to 
identify Tregs is underway. The discovery of the mutation in Foxp3 that is responsible for the autoimmune 
disease, IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked), identified Foxp3 as a 
transcription factor solely for T regulatory cells. Tregs have been shown to have multiple mechanisms of 
suppression including cell-cell contact (108, 109), death by granzyme B/perforin (110), depleting other effectors 
of IL-2 to induce apoptosis (111), and disrupting metabolic activity by inducing intracellular or extracellular 
release of adenosine nucleosides (112). Tregs have also been shown to induce indoleamine 2,3-dioxygenase 
(IDO) in DCs that influence Tregs by upregulating heme oxygenase-1 (HO-1) through 3-hydroxyanthranilic 
acid (HA), a byproduct of tryptophan metabolism (113). Induced Tregs include the Tr1 and Th3 populations 
and the primary mechanism of suppression is mediated by IL-10 and TGF-ß. Recently, a new member of the IL-
12 family, IL-35 has been shown to be required for Treg suppression (114). Although it has not been established 
if Tregs protect against human IBD, there is clear evidence of protection in mouse models. Powrie et al showed 
that transfer of naïve T cells (CD45RBhi) into SCID or RAG -/- induced colitis. Transfer of memory CD45RBlo 
cells would protect against colitis that was associated with IL-10 and TGF-ß (14-16). Tregs have also been 
shown to cure established colitis (115). CD103+ DCs have been shown to induce Tregs through TGF-ß and 
retinoic acid (116). Transfer of Foxp3+ Tregs can prevent or reverse established colitis. Mechanisms of 
suppression are thought to depend upon TGF-β, IL-10, IL-2, and CTLA-4. CTLA-4 inhibits T cell activity by 
outcompeting CD28 for binding to B7 on the APC. The impact of Tregs in immune homeostasis is manifested 
when genes critical for their suppressive functions are depleted in mouse models. For example, CTLA-4-/- and 
TGF-β-/- develop a fatal multi-organ autoimmune disease and IL-10R-/-, SMAD 3-/- (mediates TGF-β 
signaling), or IL-2-/- induce colitis. IL-2 is required for maintenance and generation of T regs. IL-10 -/- mice are 
disease free if reared in germfree conditions, however, develop colitis if housed in specific pathogen free (SPF) 
conditions indicating that the enteric flora drives colitis. The ability of B cells to secrete IL-10 in an 
inflammatory environment and to downregulate IL-1ß supports their role in the induction of peripheral 
tolerance (117). B cells were also shown to be protective in the non-obese diabetic mouse model of diabetes 
(NOD mice). LPS treated B cells express FAS ligand and secrete TGF-ß. When LPS treated B cells are 
transferred into prediabetic NOD mice, diabetes is prevented through inducing apoptosis of Th1 cells and 
downregulating APCS by TGF-β (118). Furthermore, colitis induced by transfer of pathogenic CD3 T cells 
from Gai2-/- into Rag-/- is prevented if wildtype MLN B cells are cotransferred. This protection is associated with 
an increase in regulatory CD4+CD8α+ cells (119). Further investigation will reveal whether B cells have a direct 
or indirect effect on T regulatory cells in the future and this interaction may aid in the design of therapeutics.  
Excessive effector T cell function 
The daunting task of the gut to maintain a state of hyporesponsiveness to commensals, yet mount an 
efficient T effector and/or antibody response to pathogens is mystifying. These immunological responses must 
be tightly regulated to prevent unwanted inflammation, therefore, alterations in this regulation may predispose 
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individuals to IBD. Naïve T cells migrate throughout secondary lymphoid tissues until encountering their 
cognate antigen. Upon activation and maturation into effector T cells, they are now able to migrate into 
peripheral tissues to secrete antigen specific antibody or cytokines. Migration is enabled due to the upregulation 
of chemokine receptors on the cell surface. T cells that home to the gut upregulate CCR9 and α4β7. CCR9 is a 
receptor for CCL25, expressed on IELs and endothelial cells in the lamina propria. The intestinal venules 
express mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and following binding to the integrin α4β7, 
on T cells, induces extravasation through the tissue. Activated T cells have a tropism for the tissue that the 
draining lymph node is in. For example, T cells that are activated in the MLN or Peyer’s patches home to the 
gut whereas T cells activated in cutaneous lymph node’s migrate to the skin (120). Depending on the 
environment, CD4 T cells may differentiate into Th1, Th2, Th17 or regulatory effector cells (121). Th1 cells 
predominantly secrete IFN-γ and IL-12 to control intracellular infections, whereas Th2 cells aid in humoral 
immunity by secreting IL-4, 5, 9, or 13. Interleukin 17 produced by Th17 cells recruit neutrophils, stimulate 
endothelial cells, macrophages, epithelial cells, and fibroblasts to secrete IL-1, IL-6, TNF-α, NOS-2, 
metalloproteases and chemokines in response to external bacterial and fungal infections (121). Induced Foxp3+ 
T regulatory cells can upregulate CD25 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) and secrete IL-10 or 
TGF-β in response to inflammatory cytokines (122). A fine-tuned balance of all T cell lineages are required to 
maintain homeostasis, and an immune imbalance may trigger IBD in susceptible individuals. CD4+ T cells have 
been implicated in IBD due to a report of patients having anti-CD4 antibodies (123). Also treatment of CD 
patients with anti-TNF antibodies increased CD4 T cell apoptosis as lesions decreased indicating that TNF 
secreting effector cells may be contributing to the pathogenesis of CD (124). Previous reports of IBD 
pathogenesis state that CD is predominantly Th1 driven having increased IFN-γ and IL-12 (p70) secretion. 
Alternatively, UC is mainly Th2 driven due to increases in IL-4 and IL-13. Recently, CD etiology has expanded 
to include IL-17 and IL-23. Naïve T cells develop into Th17 cells in the mouse, in the presence of TGF-β and 
IL-6, compared to IL-1 and IL-6 in humans. Mice deficient in TGF-β do not have Th17 cells and there is 
increasing interest in the role that T regulatory cells play in the development of Th17 cells. Expansion of IL-17 
cells requires IL-23 (p19) and recent evidence suggests that IL-21 regulates Th17 cells (125). IL-23 (p19 & 
p40) contributes to Th1 mediated colitis in the following models: IL-10-/- mice (126, 127), transfer of CD45Rbhi 
cells (127), induction of pathogenic antigen-specific T cells (128), colonization of immune deficient mice with 
Helicobacter hepaticus (129), and CD40 mediated activation of innate immunity (130). Th17 popularity has 
increased due to the finding of increased IL-17 in patients with autoimmune diseases like RA, MS, asthma, and 
IBD (131, 132). While IL-12 and IFN-γ are required for killing intracellular bacteria, IL-17 and IL-23 are 
required for killing extracellular bacteria and fungi (121). Yen et al showed mice possessing depletions in both 
IL-10 /IL-12 (p35), but not IL-10/IL-23 (p19) developed spontaneous IBD indicating that disease manifestation 
required the presence of IL-23 (126). There are many knockout or transgenic animals models resulting in 
spontaneous IBD (see Table 1). Many have hypothesized that the target of these pathogenic CD4+ T cells is the 
intestinal flora since there are many knockout or transgenic mouse models that have ameliorated or no clinical 
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signs of IBD when housed in SPF or germfree environments. Cong et al showed that CD4+ T cells from 
C3H/HeJBir mice that spontaneously develop colitis, were reactive to enteric bacterial antigens (133). Transfer 
of the reactive CD4 T cells into C3H/HeSnJ scid/scid mice induced colitis indicating that the enteric flora drives 
aberrant effector T cells in the pathogenesis of IBD.  
 
 
Innate immunity Adaptive immunity 
Mdr1α, A20, NEMO, Tir8, NFATc2, 
STAT3, GPX1/2, XBP1, Muc2 and 
Keratin8, NCAD and GFAP-HA 
IL-2, IL-2Rα, IL-2Rß, Gai2, Smad3, 
TNF(ARE), CBI-b, IL-10, TGFβ, CdCS, 
TCRα, WASP, and Runx2, HLA-B27, 
CD3ε, IL-7, gp39, LIGHT, STAT4, IL-
15 
Table 1. Spontaneous and transgenic models of IBD mediated by genes 
associated with innate or adaptive immunity (134).  
 
Epithelial Defense in Response to Microbial Interactions  
There are many defenses against microbes within the many physiological layers of the gut. Epithelial cells 
lining the GI tract are an innate barrier of defense, protecting the lamina propria cells from the contents of the 
lumen. The role of these innate sensors is critical in maintaining the homeostasis of the gut since most of the 
initial interactions between commensal and pathogenic microbes occur through the epithelial cells. Since the 
enteric flora are critical to IBD development, knowledge of epithelial and microbial interactions is important in 
the discovery of therapeutics and prevention of disease.  
A single layer of polarized epithelial cells, spanning 200 square meters acts as a mechanical, chemical and 
biogical barrier to the environmental antigens of the lumin. A thick glycocalyx lines the epithelium and prevents 
adhesion by mucus. Tight junction extracellular adhesive proteins including occludins, claudins and jam 
associate with zonula occludens, zonula adherens and macula adherens to make up the paracellular barrier of 
the epithelium. A breach in permeability and altered tight junctions have been associated with IBD (135).  
Innate receptor recognition of enteric flora: PAMPs- NF-κB.  
Pathogen associated molecular patterns (PAMPs) are conserved structures on bacteria and trigger innate 
signaling cascades after binding pathogen recognition receptors (PRRs). PAMPs include LPS, peptidoglycan, 
lipoteichoic acid, flagellin, non-methylated DNA and double stranded RNA. Epithelial cells express PRRs 
including TLR2, 3, 4, 5 and and TLR9. Healthy individuals have a low expression of TLR indicating a 
hyporesponsiveness to luminal flora; however, elevated TLR expression is associated with IBD. A recent study 
found a greater expression of TLR2 and TLR4 in colonic biopsy samples from children with either freshly 
diagnosed or relapsed IBD (136). Mice having a depletion in TLR2, 4, 9, or MyD88 genes have a greater 
sensitivity to acute DSS induced colitis that wildtype controls indicating the importance of NF-κB signaling in 
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epithelial health. Some T cell mediated colitis models including IL-2 -/- and CD4+CD62L+ transfer models are 
also predisposed to IBD in TLR9-/- and MyD88-/- mice (83). Interestingly, when TLR agonists are 
prophylactically given by oral or systemic routes in various acute and chronic models of colitis, mice were 
protected from colonic inflammation (83). One downstream pathway of TLR signaling is NF-κB activation and 
proinflammatory cytokines including TNF-α, IL-1β, IL-12 (p40) and IL-23  (p19) that are dependent upon NF-
κB activation are upregulated in IBD patients (137). NF-κB expression ensures homeostasis by controlling 
antimicrobial peptide secretion, cell survival, and permeability. Innate regulation of NF-kB activity is apparent 
following subsequent TLR ligation resulting in reduced NF-κB activity. The reduction of NF-κB activity is 
through multiple inhibitors of NF-κB including toll interacting protein (Tollip), IRAK-M, single 
immunoglobulin IL-1 receptor (SIGIRR), A20, NOD2, and PPARγ. Although PAMPs are shared by both 
commensals and pathogenic bacteria, the structure is altered. Commensal Gram-negative bacteria have a lipid-A 
component that is pentacylated and pathogenic bacteria have a hexacylated lipid A, thus enhancing the agonistic 
affinity to the LPS receptor in pathogenic bacteria (138). However, some bacteria have evolved strategies to 
hide by reducing acetylation of lipid A. Salmonella contains a bacterial deacetylase, PagL, that deacetylates its 
lipid A (139).   
Antimicrobial peptides.  
Other innate mechanisms of the host in recognition of the microbiota include secretion of antimicrobial 
peptides. Paneth cells in the crypts of the small intestine are the primary producer of β−defensins (HD5 and 
HD6) in response to NOD2 activation, however, β−defensins can be made by epithelial cells in other types of 
tissues including skin, respiratory tract and GI tract (140). Defensins are a class of small and cationic 
antimicrobial peptides that kill bacteria by disrupting their cell membrane. Crohn’s disease patients with NOD2 
mutations have decreased production of β−defensins indicating that NOD2 regulates this function. Human 
β−defensin-1 (HBD1) is constitutively secreted in the colon and small intestine whereas β-defensin-2 (HBD2) 
is an NF-κB target inducible by bacterial stimulation under inflammatory conditions in the colon. HBD3 is an 
interferon-γ regulated gene secreted by the colon and small intestine, that has been reported to be upregulated in 
UC (141). Cathelicidin LL37/hCAP18 in humans in constitutively produced by epithelial cells in the colon. One 
study reported that stimulation of TLR2 and TLR4 by LPS and peptidoglycan upregulated β-defensin 
production demonstrating the protective features of the epithelium (142).  
Apoptosis of IECs.  
The rapidly proliferating intestinal epithelium adapts to environmental conditions by turning over every 24-
96 hours when new cells proliferate and migrate up the crypts to replace apoptosed cells. Although commensal 
bacteria are not invasive, pathogenic bacteria can infect cells and disrupt this proliferation-apoptotic cycle.   
Some bacteria, like enteroinvasive E. coli, can induce apoptosis of epithelial cells that can potentially benefit 
the host by depleting infected cells or the bacteria by delaying signals to innate immune cells to destroy the 
bacteria (143). Other bacteria have virulence factors that allow invasion and or damage of the epithelial cell. 
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Following colonization with a pathogenic organism, the epithelial cell responds by inducing apoptosis or 
inflammation, depending on which is more beneficial for survival of the host.  
Interaction of bacterial virulence factors on epithelium.  
Not all bacteria have to be invasive to induce damage to epithelial cells. Vibrio cholerae and enteroxigenic 
E. coli (ETEC) secrete toxins following endocytosis, that bind to G proteins and activate adenylyl cyclases. 
Upregulation of cAMP activates protein kinase A and ion transporters leading to diarrhea (144). Another 
example of a powerful virulence factor is invasin. Yersinia express this surface attachment factor that binds to 
integrins on the apical side of M cells in the gut. Binding of invasin to integrins induces bacterial uptake into the 
cell by actin rearrangement. Many diseases manifest following this invasion tactic including gastroenteritis by 
Y. pseudotuberculosis and Y. enterocolitica and the plague by Y. pestis. Helicobacter pylori has virulence 
factors including type IV secretion systems that aid in attachment. H. pylori contains an omp-related protein, 
BabA that binds to the blood group antigen Lewis b (Leb) which is produced by the pit and surface mucous cells 
of the stomach. Once attached, H. pylori  produces CagA and the vacuolating toxin, VacA. VacA functions to 
block the endosome pathway, thus inhibiting intracellular trafficking. Mutations in CagA result in less IL-8 
secreted from H. pylori infected gastric epithelial cells and CagA+ specimens from gastric biopsies in patients 
had increased IL-8 compared to CagA- strains (145, 146). Type III secretion systems (TTSS) are common in 
gram negative bacteria and mediate the transport of bacterial effector proteins into the cell cytosol of eukaryotic 
cells by interacting with the actin cytoskeleton and disrupting signal transduction pathways. Many bacteria have 
been reported to have TTSS including Yersinia, Salmonella, Shigella, Escherichia, Pseudomonas, Bordetella, 
Burkholderia, and Chlamydia (147). Pathogenicity islands encode the genes for TTSS and bacteria that have 
mutations in these genes lack pathogenicity. Bacterial flagella are produced in bacteria to promote motility and 
thus aid in colonization, adhesion, invasion, and secretion of virulence factors (148). Recently, IgG specific for 
flagella from the Clostridium phylogenetic cluster XIVa has been demonstrated in the serum of patients with 
CD and from a murine colitis model (149, 150). 
Epithelial secretion of chemokines as a microbial defense.  
Epithelial cells secrete many chemokines and cytokines in response to microbes. Following infection, the 
epithelium undergoes activation that results in increased NF-κB or AP-1 expression leading to proinflammatory 
or chemokine secretion (151). CCL5/RANTES (regulated upon activation, normal T-cell expressed and 
secreted), and CCL2/MCP-1 (monocyte chemotactic protein-1) are CC chemokines that can recruit monocytes 
and promote transepithelial migration of TCRαβ+ and TCRγδ+ T cells (152). CC chemokines including 
RANTES and MCP-1 have been reported to be elevated in active colitis and correlate with increased leukocyte 
infiltration in colonic tissue (153-156). CXCL8 (IL-8) is a neutrophil attractant secreted from the basolateral 
side of the intestinal epithelium in response to invading bacteria or bacterial colonization. Following epithelial 
secretion of CXCL8, neutrophils will translocate across the epithelium and enter the gut lumen, where they can 
secrete antimicrobial peptides. IL-8 has been implicated in the pathogenesis of IBD due to elevated levels of 
protein observed in active inflammatory tissues of IBD patients (157). The murine homologue of IL-8 is MIP-2 
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(158). CCL20 (MIP3α) is a dendritic and T cell chemoattractant, constitutively secreted by the epithelium 
overlaying Peyer’s patches that is upregulated following inflammation. Epithelial cells secrete many other 
chemokines to recruit monocytes and T cells including MCP-1, CCL22, CCL9, CCL10, CCL25 and CCL28 
(159-162).  
Effect of microbiota on gut homeostasis.  
The commensal flora is required to maintain homeostasis in the gut. Colonization of the gut flora begins directly 
after birth as bacteria multiply becoming more specialized and diverse. As stated previously, the enteric flora 
benefit the human host in many ways. For example, E. coli, Bacteroides spp. and Clostridium spp. deconjugate 
and dehydroxylate bile acids (163). Eubacterium converts cholesterol to coprostanol and Clostridium ramosum 
converts bilirubin to urobilinogen (164, 165). Vitamin K is also produced by many bacteria including 
Lactobacillus and Bifodobacterium (166). Germfree mice display epithelial deformities including: hypoplasia of 
intestinal villi, shorter crypts, fewer cells, cuboidal morphology of enterocytes, lack of development of 
lymphoid follicles, luminal mucus inspissation (don’t have flora to degrade secreted mucus glycoproteins). 
However, re-colonization with enteric flora reverse these conditions (167). Oral gavage of germfree mice with 
Salmonella typhimurium induced a two-three fold increase in M cells, crypt depth and enterocyte migration 
after seven days (168).  Enteric flora also provide competition of niches and nutrients to protect against 
pathogenic bacteria. Germfree bacteria have an enlarged cecum compared to conventionally colonized animals, 
which is partially resulting from expansion of undegraded mucus due to a lack of bacteria that produce 
glycoside hydrolases like Peptostreptococcus micros, Ruminococcus and Bifidobacterium (169, 170). 
Homeostasis of the adaptive immune system is also influenced by the commensal flora. Germfree mice produce 
less IgA and have less circulating B and T cells compared to conventional flora mice (62). The commensal flora 
also affects the GALT in that colonization of germfree mice with flora induces a larger number of αβTCR 
intraepithelial lymphocytes (171). A preimmune antibody repertoire also depends upon the presence of the flora 
by promoting somatic diversification (172). 
Induction of tolerance 
Central tolerance  
Central tolerance is defined as the prevention of immunological responses to self antigen induced in 
developing lymphocytes. This process occurs in the thymus for T cells and the bone marrow for B cells. 
Following TCR rearrangement and positive recognition of MHC/peptide in lymphocyte development, cells are 
faced with negative selection. Negative selection ensures deletion of cells with a high affinity for self peptide 
and mechanisms include clonal deletion, anergy, receptor editing, or development of regulatory cell lineages 
(173). These processes are highly regulated and autoimmune diseases can arise if mutations occur in key genes. 
For example, mutations in the autoimmune regulator (AIRE) gene inhibit clonal deletion and result in 
autoimmune polyendocrinopathy-candidiasis-ectodermal-dystophy syndrome (APECED) (174). Another 
autoimmune disease, immunodysregulation, polyendocrinopathy and enteropathy, X-linked syndrome (IPEX) 
occurs due to a mutation in forkhead box P3 (FOXP3), a transcription factor required for T regulatory 
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development (175). The body has also conceived a secondary measure to induce tolerance in the scenario that 
cells escape primary lymphoid tissues and migrate to the periphery to encounter alternate self proteins: 
peripheral tolerance.  
Peripheral/Oral tolerance  
This phenomenon was described almost 100 years ago by Besredka referring to anaphylactic 
sensitization to milk proteins (176). Immunological non-responsiveness to antigens that were previously 
administered by the oral route is referred to as oral tolerance. This form of peripheral tolerance was thought to 
evolve to prevent unwanted responses to dietary antigens and commensal flora. Oral tolerance has been 
observed in animal models by diminished immunological responses to antigen that was repeatedly ingested in 
large doses followed by systemic immunization with the same antigen (177). There are two reported 
mechanisms of oral tolerance. First, oral antigens repeatedly given at low quantities induce regulatory cell 
driven tolerance. Mice orally challenged with myelin basic protein (MBP) were protected from experimental 
autoimmune encephalomyelitis (EAE). Mesenteric lymph node CD4+ cells were cloned from these orally 
tolerized mice and were found to secrete TGF-β and IL-10 (178). Another study found that cells from Peyer’s 
patches of MBP orally tolerized mice secreted TGF-β and suppressed proliferation of other cells in vitro and 
protected mice from EAE following cell transfer (179). Other studies have shown that oral antigens induce 
increased percentages of CD4+CD25+ T cells that express CTLA4 or Foxp3 and secrete IL-10 and TGF-β. 
When transferred into naïve mice, these cells can transfer tolerance (180, 181). The regulatory cytokines 
secreted from T regulatory cells act by bystander suppression, therefore, while the antigen to induce regulation 
must be specific, the downstream effects of suppression are not. This mechanism of suppression has enabled 
researchers to harness the power of T regulatory cells for therapies for autoimmune diseases like arthritis, EAE 
and diabetes (182). A second mechanism of oral tolerance is that a single, high dose of antigen induces deletion 
or anergy (183-185). However, recent work indicates that the “anergic” T cells may still be capable of secreting 
suppressive cytokines signifying an overlap of oral tolerance mechanisms (186). Other cells that secrete 
suppressive cytokines may also contribute to maintaining tolerance including CD8+ T cells, γδ T cells, NKT 
cells, B cells, macrophages, immature DCs and plasmacytoid DCs (187-191). CD8+CD28- T cells with 
regulatory characteristics expand after interaction with epithelial cells in the gut and are lacking in patients with 
active IBD indicating that these cells may contribute to IBD (189, 192). IL-10 secreting B cells that have a 
lower expression of CD80/86 have also been shown to be protective in colitis (193). Plasmacytoid DCs have 
been shown to contribute to T regulatory differentiation (188). Other less conventional suppressors like 
neuropeptides include vasoactive intestinal peptide (VIP), glucocorticoids, oestrogens, cortistatin, urocortin and 
adrenomedullin have been reported to contribute to T regulatory cell development either directly, or indirectly 
through DC maturation with LPS as well (98, 194). 
Mucosal Inflammation-breaking tolerance  
Three factors account for the maintenance of tolerance to the commensal microbiota: characteristics of the 
flora, the epithelium, and the lamina propria immune cells. For example, an impaired ability of bacteria to 
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attach and invade the mucosa; having defective sensors of molecular PAMPs; and immune cells that produce 
anti-inflammatory cytokines including TGF-β and IL-10 all promote tolerance (195, 196). Deregulation of these 
attributes may contribute to inflammation and development of IBD. Evidence for a breach in tolerance 
contributing to IBD is supported by experiments from IBD patients. Compared to healthy individuals, T cells 
from IBD patients proliferate and secrete cytokines in response to antigens from their fecal extracts (101). 
Furthermore, mononuclear cells from healthy, non-colitic mice do not proliferate in response to their own 
bacterial antigens, but greatly proliferate to bacterial antigens from other mice (197). However, during 
inflammation induced by TNBS colitis, mice have broken tolerance as displayed by proliferation in response to 
enteric flora that is ameliorated with either anti-IL-10 or anti-IL-12 treatment (197). Additional evidence that 
IBD patients have broken tolerance to the flora is evident by increased antibodies to enteric flora constituents 
(198). 
  
Objectives of Dissertation 
 In conclusion, review of the literature indicates that while progress has been made towards the 
pathogenesis of IBD, the exact mechanisms addressing why occurrences typically develop in the second-third 
decade of life and how the resident flora contributes to the development of IBD still need to be determined. 
Furthermore, differentiation by the mucosal immune response between commensal and pathogenic organisms 
may play a key role in why probiotic treatments have controversial effects in IBD therapy. Therefore, the 
mechanisms of initial host responses to novel provocateurs may elucidate the etiology of IBD. 
The specific aims of this dissertation were to 1) develop a multiple-hit model of colitis to characterize 
the adaptive antigen-specific immune responses following the disruption of homeostasis of the resident 
microbiota following an environmental inflammatory trigger in the development of IBD, 2) determine whether 
the increased sensitivity to DSS was a unique feature of H. bilis colonization, and 3) evaluate the induction of 
chemokines and proinflammatory cytokines from murine epithelial cells by H. bilis or E. coli exposure.  
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Abstract  
Inflammatory bowel disease is a chronic inflammation of the gastrointestinal tract (GI) that develops in part as a 
result of an aberrant immune response to enteric bacteria in the GI tract. Prior studies indicate that Helicobacter 
bilis colonization of immune competent, defined-flora (DF) mice induced antigen-specific responses to their 
resident flora, in the absence of colitis.  We hypothesize that H. bilis colonization of DF mice perturbs mucosal 
homeostasis and, thus, alters tolerance to the commensal flora and increases the host’s sensitivity to an 
inflammatory insult.  Defined flora mice were colonized with Helicobacter bilis for up to 20 weeks prior to 
treatment with low-dose (1.5%) dextran sulfate sodium (DSS). Mice were evaluated for gross and histological 
lesions as well as cellular and humoral responses in comparison to controls. In comparison to DSS treated or H. 
bilis colonization alone, mice dually treated with H. bilis and DSS developed significantly (p < .05) increased 
gross and histopathological lesions including cecal atrophy, decreased colon length, and histological 
inflammation. Serum IgG2a responses to antigens derived from the enteric flora were increased compared to 
controls. Evaluation of the proximal colon indicated an increase in mucosal IL-17, IFN-γ, and TNF-α after 
colonization and/or DSS treatment. The magnitude of antigen-specific T cell proliferation increased with time, 
as Foxp3 expression declined; however, lesions did not increase in severity. Susceptibility to DSS-induced 
colitis was associated with increased antigen-specific reactivity to the enteric flora and mucosal expression of 
inflammatory cytokines. In conclusion, these studies demonstrate that perturbation of the microbial ecology 
following colonization with a mildly pathogenic bacteria, such as H. bilis, may induce antigen-specific Th1 and 
Th17 immune responses, thus, predisposing the host to colitis following exposure to an otherwise innocuous 
inflammatory insult. 
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Introduction 
Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract primarily 
composed of ulcerative colitis (UC) and Crohn’s disease (CD). The exact etiology of IBD is unknown, but is 
thought to be multi-factorial. Previous studies indicate that genetics and environment strongly associate with the 
development of an aberrant immune response resulting in IBD (1, 2) . There is much evidence for the impact of 
the enteric flora in the development of IBD. Biopsies taken from patients with chronic IBD indicate a denser 
bacterial population and thicker mucosal layer in lesions compared to healthy individuals (3, 4). Furthermore, 
50% of CD patients have positive serological responses to bacteria like Saccharomyces cerevisiae or bacterial 
components components including Cbir flagellin, OmpC, and I2 (5). Murine models of IBD reiterate the 
significance of the gut flora (6-10). Models including genetic knockouts, cell transfer, and chemically induced 
models of disease are very diverse, yet they share a common theme: depletion of flora ameliorates or eliminates 
clinical signs of disease. For example, IL10-/- mice spontaneously develop clinical signs of colitis when housed 
under conventional conditions; however, in a germ free environment, IBD does not occur unless the mice are 
reconstituted with a bacterial microbiota (11, 12). Other evidence for the importance of the enteric flora can be 
shown by twin studies. The occurrence of IBD that manifests in identical twins that share an IBD susceptible 
locus is only 50% (13). This suggests that a genetic predisposition only accounts for half of the IBD outbreaks 
and environmental factors may account for the other half of disease. Lastly, clinical therapies for IBD patients 
include the administration of broad spectrum antibiotics like metronidazole and ciprofloxacin (14-17). While 
antibiotics do not cure the disease, they deplete species of the enteric flora and lead to a temporary improvement 
of IBD. Collectively, this evidence indicates that the enteric flora plays an vital role in the development of IBD 
(18-20). 
 Although IBD is associated with detrimental immune responses to the enteric flora, it is likely that 
there are multiple factors associated with the communication between the host and microbial environment and 
deficiencies in these interactions may manifest in colitis. It has been hypothesized that ‘multiple hits’ or defects 
in the innate, adaptive, or regulatory immune responses are required to induce susceptibility to IBD in immune 
competent individuals (21). To develop a multiple hit model of colitis in immune competent, defined flora mice, 
we introduced Helicobacter bilis as a novel provocateur to the microbial ecology. H. bilis is a Gram-negative, 
microaerophilic, spiral to curved rod. This fusiform bacterium has 3-14 flagella and periplasmic fibers wrapped 
around the cell and has been isolated from the liver, intestine, and bile of aged, inbred mice associated with 
hepatic lesions (22). Antibody responses to Helicobacters species other than H. pylori have been detected in 
serum from IBD patients (23). H. bilis has also been associated with IBD-like lesions in immunocompromised 
mice (24-26). For example, SCID mice colonized with H. bilis had clinical signs of typhlitis by 12 weeks post-
infection (24). Previous experiments from this laboratory indicated that H. bilis colonization of immune 
competent, defined flora (DF) C3H mice, induced immune reactivity to the resident commensal flora (27). 
Furthermore, it has been reported that T cells reactive to antigens from the commensal flora can mediate chronic 
IBD (9). Recent microarray data indicated that H. bilis significantly increased gene expression associated with 
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proteolysis, glycoprotein synthesis, protein metabolism and immune response and significantly downregulated 
fatty acid metabolism, lipid metabolism and carboxylic acid metabolism genes (Zhiping Liu-submitted for 
publication). Although H. bilis colonization results in mild lesions, it is conceivable that the gene expression 
changes and newly induced immune reactivity may increase host susceptibility to an environmental 
stressor/inflammatory insult. We hypothesized that the introduction of a novel bacterial provocateur into the 
established intestinal flora will perturb host mucosal homeostasis, inducing aberrant immune responses to the 
resident flora (hit #1-H. bilis), resulting in increased vulnerability to an environmental/inflammatory insult/ 
stresser (hit #2-dextran sulphate sodium (DSS)). IBD patients typically have relapses in inflammatory episodes 
between periods of quiescence. These active inflammatory episodes tend to correspond to stressful life events 
(28, 29).  Evidence for the effects of stress on the gastrointestinal tract include alterations in intestinal 
permeability, increased PMN infiltration and epithelial dysfunction including increased macromolecular protein 
uptake (29-31). Stress has been shown to enhance colitis in rats and may predispose a person to IBD (32, 33). 
DSS has been commonly used to induce acute or chronic colitis in mice as the resultant clinical signs are similar 
to human colitis (diarrhea, weight loss, bloody stool) (34-39). The acute phase of inflammation induced by DSS 
results in macrophage infiltration. Lesion restitution is characterized by the recruitment of lymphoid cells (34). 
Administration of DSS results in exposure of luminal contents to lamina propria cells and the severity of 
clinical signs positively correlates to the dose of DSS. Furthermore, since clinical signs of DSS are similar to 
the effects that stress can have on the gut including increased permeability and PMN infiltration, we wanted to 
use this chemical as an inflammatory stressor/trigger to expose innate immune cells to luminal antigens. While 
previous studies have indicated that colonization with specific bacteria can trigger IBD in immunocompromised 
mice, this is the first study to show that colonization with a novel, enteric bacterial provocateur can predispose 
the host to colits in an immuno-competent, ‘multi-hit’ mouse model (40).  
To test the hypothesis that a novel microbial provocateur may predispose an immuno-competent host 
to IBD, defined flora mice were colonized with H.bilis for 3-20 weeks at which time they were treated with a 
low dose [i.e. environmental/inflammatory trigger] of DSS. The results of these studies demonstrate that H.bilis 
colonization induced antigen specific immune reactivity to the enteric flora including antibody responses, 
increased lesion scores, and increased inflammatory cytokines that may contribute to susceptibility to DSS 
exposure. H. bilis colonization increased sensitivity to low dose DSS manifested by significantly (p < .05) 
elevated macroscopic and histological scores that were associated with enhanced host immune responses as 
demonstrated by development of antigen-specific T cell proliferation. 
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Materials & Methods 
Animals 
  
Six- to eight-week old male and female gnotobiotic C3H/HeN:Tac mice harboring a defined flora  consisting of 
the altered  Schaedler’s  flora (ASF 356: Clostridium spp. Cluster XIV; ASF 360: Lactobacillus acidophilus; 
ASF 361: Lactobacillus murinus; ASF 457: Mucispirillum schaedleri; ASF 492: Eubacterium plexicaudatum; 
ASF 500: Low-G+C-content gram-positive; ASF 502: Clostridium spp. Cluster XIV; ASF 519: Bacteroides 
distasonis) were originally obtained from Taconic Farms (Albany, NY) and are now bred and maintained under 
gnotobiotic conditions at ISU. All mice were certified free of Helicobacter prior to use and mice were routinely 
screened for all eight ASF members. Antigen presenting cells (APCs) were also prepared from defined flora, 
C3H/HeN:Tac mice certified free of Helicobacter. All experiments were approved by Iowa State University 
Animal Care Committee.  
 
Experimental Design  
Defined flora mice were separated into four groups of five to six mice per group: 1) Non-colonized only, 2) 
Non-colonized + DSS, 3) H. bilis colonized only and 4) H. bilis colonized + DSS. Groups three and four were 
inoculated by oral gavage with > 2 x 107 H. bilis CFU in 0.3 ml of Brucella broth three times over a 3-day 
period. Helicobacter colonization was confirmed by species-specific fecal PCR one to two weeks after 
inoculation and at necropsy by urease broth. Following 3-20 weeks postinfection  (PI), groups two and four 
received filter sterilized 1.5% DSS (molecular weight=36-50 kilodaltons, MP Biomedicals, Irvine, CA) in 
deionized drinking water for five days, followed by four days of regular sterile water. Groups one and three 
received sterile water throughout the entire experiment. Immediately following the four day restitution period, 
mice were euthanized. Ceca were blindly scored as 0=healthy, normal control, 1=mild atrophy, 2=apparent 
mucus and atrophy, 3= severe atrophy, no cecal contents, overt mucus and 4= 3 + blood and colon length was 
measured. Colonic tissue samples were collected and fixed in 10% buffered formalin and submitted for routine 
histopathological evaluation. Mesenteric lymph nodes (MLN) were collected and enriched for CD4+ T cells 
using nylon wool columns (41). Spleen cells were harvested from DF donor mice one day prior to necropsy for 
antigen presenting cells (APCs) and incubated with ASF antigens (200 µg/ml) overnight following mitomycin 
C treatment (Fisher). APCs were plated at a 1:1 ratio with CD4+ T cells and stimulated with the following 
treatments: APC (no stimulant), pooled APC (all 8 ASF antigens), or anti-CD3/28 (2/.5µg/ml) for 72 hours. 
Supernatants were collected and analyzed by multiplex fluorescent bead assay for the following cytokines: IL-2, 
IL-6, IL-10, IL-12 (p40), IL-17, IFN-γ, and TNF-α. In addition, samples were assessed for antigen-specific 
CD4+ T cell proliferation and serum antibody responses and proximal colon was assessed by quantitative RT-
PCR analysis for gene expression.  
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Preparation of Bacterial Antigens 
Each member of the ASF (ASF360, ASF361, ASF356, ASF457, ASF492, ASF500, ASF502, and ASF519) 
were grown in anaerobically prepared medium as previously described (27). Bacterial antigens (e.g. all eight 
ASF strains) used for ELISA or for stimulation of lymphocyte cultures were prepared from the lyophilized 
cells. The cell suspension was placed on ice and sonicated for 5 minutes to prepare whole cell sonicates (WCS). 
WCS were sterilized by UV light irradiation and stored at –20 °C until use. Sterility of each individual WCS 
was confirmed bacteriologically.  
 
Gene Expression via Real Time RT-PCR  
Total RNA was extracted from 20 mg of proximal colon using the RNAeasy Mini Kit (Qiagen) as described by 
the manufacturer. The RNA samples were quantified by ND-1000 spectrophotometer (Nanodrop technologies) 
and treated with TURBO DNA-free DNase at 2U/µl (Ambion) to eliminate genomic DNA contamination. 5 µg 
of RNA was reverse transcribed into cDNA by SuperScript™ III First-Strand Synthesis System (Invitrogen, 
San Diego, CA). cDNA was amplified using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen). 
The following PCR conditions were used: 95°C for 10 minutes followed by 40 cycles of amplification (95°C for 
10 seconds, 56°C for 5 seconds, and 72°C for 10 seconds). Primers for glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH−forward primer: 5’- TCACCACCATGGAGAAGGC-3’, reverse primer: 5’-
GCTAAGCAGTTGGTGGTGCA-3’) IFN-γ ( forward primer: 5’- TCAAGTGGCATAGATGTGGAAGAA-3’, 
reverse primer: 5’-TGGCTCTGCAGGATTTTCATG-3’), TNF-α ( forward primer: 5’-
CATCTTCTCAAAATTCGAGTGACAA-3’, reverse primer: 5’-TGGGAGTAGACAAGGTACAACCC-3’ ) 
and IL-17A (forward primer: 5’-CTGAGAGCTGCCCCTTCACT-3’, reverse primer: 5'-
CCACACCCACCAGCATCTTC-3’) were used. The qRT-PCR was performed using Applied Biosystems 
GeneAmp™ 5700 Sequence Detection System.  Standard curves for each gene were made using a series of 
cDNA dilutions. The relative RNA quantity of each gene was normalized to GAPDH (42). 
 
Histopathology . 
Sections of cecum and colon were fixed in 10% buffered formalin. The tissues were routinely processed, 
embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin. Tissues sections from each 
mouse were scored for severity of mucosal epithelial damage, glandular alterations, and magnitude/character of 
the lamina proprial cellular infiltrate. Histological sections were evaluated blindly by J.M. Hostetter and scores 
ranged from 0 (healthy) to 5 (diseased) for each parameter of erosion and inflammation reported by a previously 
defined scoring system (27).  
 
Analysis of Ag-Specific Serum Antibodies by ELISA.   
Serum antibody levels in mice were determined by enzyme linked immunoabsorbant assay (ELISA). Briefly, 
96-well plates (Costar-3590) were coated with 100 µl/well of whole cell sonicate (WCS) at 10 µg/ml derived 
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from the individual members of the altered Schaedler’s flora (ASF) and H. bilis diluted in PBS (pH 7.4) 
overnight at 4ºC. Plates were washed three times in PBS/Tween 20 (.05%) and blocked with 280 µl/well 2% 
gelatin diluted in PBS/.05%Tween 20/2% FBS for two hours at room temperature. Plates were washed three 
more times with PBS/.05%Tween 20 prior to addition of 100 µl/well serum samples diluted 1:200 in 
PBS/Tween/2% FBS overnight at 4ºC. Plates were washed five times with PBS/.05%Tween 20. Then, 100 µl of 
1:2000 diluted alkaline phosphatase -conjugated goat anti-mouse IgG (H&L), IgG1 or IgG2a (Southern 
Biotechnology) in PBS/Tween/2% FBS was added per well and incubated for 2 hours at room temperature. 
Prior to washing five times with PBS/.05%Tween 20, wells were developed for a colormetric reaction using 100 
µl of p- nitrophenyl phosphate (Sigma 104) (1 mg/ml) at room temperature. Absorbance was measured using an 
ELISA reader (405 nm). 
Analysis of Ag-Specific Serum Antibodies by SDS-PAGE & Western blots  
Duramide pre-poured 12% tris-glycine gels (Cambrex) were loaded with Precision Plus protein standards dual 
ladder (Biorad) or 7 µg of ASF WCS that had been boiled in SDS-PAGE buffer for 10 min at 90ºC and run in a 
electrophoresis unit at 125 volts for approximately 1.5 hours. Following electrophoresis, gels were either 
prepared for western blots (below) or fixed in deionized H20/50% methanol/14% acetic acid for 30 minutes and 
rinsed in deionized H20. Gels were incubated on rocker in Gelcode Blue (company) overnight at 4ºC and 
washed several times in deionized H20.  
After running the gel as described above, it was washed briefly in deionized H20 and equilibrated in transfer 
buffer (25mM Tris, 192 mM glycine, 20% methanol and deionized H20) for approximately five minutes. PVDF 
membrane was pre-wet in methanol to prevent gel swelling and keep proteins absorbed to the membrane and 
sandwiched between blot paper and gel prior to loading into Cambrex cassettes. Cassettes were placed into a 
transfer unit with an ice block and run at 150 mAmps (constant currant) for 90-120 minutes. Membranes were 
washed three times in PBS/Tris/Tween20 and blocked in PBS/Tris/Tween20/1% gelatin overnight at 4ºC. 
Primary antibody (1:250 dilution of pooled serum from H. bilis colonized mice) was incubated with membranes 
for 2 hours at room temperature. Membranes were washed three times in PBS/Tris/Tween20 and then incubated 
with secondary antibody (anti-IgG2a at 1:1000 dilution) for 2 hours at room temperature. Membranes were 
washed three times in PBS/Tris/Tween20 and incubated in substrate (Naphthol AS-MX/Fast red/Tris solution) 
at room temperature until desired color was reached (approximately 20 minutes) and placed in deionized H20 to 
stop the reaction. 
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Preparation of Antigen Presenting Cells (APCs)/Mitomycin C Treatment 
Spleens were recovered from three adult C3H/HeOuJ mice and homogenized to prepare single cell suspensions 
in complete RPMI 1640, (Cellgro) containing 5% FBS, 1M HEPES, essential amino acids, non-essential amino 
acids, 1 mM sodium pyruvate, (2 mM) L-glutamine, penicillin-streptomycin, 25 µg/ml gentamycin and 175 µl 
2-β-mercaptoethanol. Antigen pulsed APCs were prepared as described by Cong et al (43). Briefly, two 
separate aliquots of 20 x 106 cells/5 ml were placed into two 15 ml tubes along with 200 µg/ml (total protein 
content) of all eight ASF WCS (25 µg/ml each) added to one aliquot or medium alone was added to the other 
aliquot of APCs and both were incubated overnight at 37ºC. The APC preparations were then incubated in the 
presence of mitomycin C (50 µg/ml final concentration) at 37ºC for 30 to 45 minutes. The cell suspensions were 
washed five times using RPMI supplemented with 5% fetal calf serum (FCS) and antibiotics (41). 
 
T cell Enrichment  
T cells were enriched using nylon wool columns as previously described (41). Briefly, 0.6 g nylon wool was 
packed to the 6 ml line of a 10 ml syringe and autoclaved. Columns were then incubated with pre-warmed FCS 
supplemented hank’s balanced salt solution (HBSS) for 1 hour at 37 ºC. Pre-warmed medium was added to 
wash the column prior to the addition of 1 x 108 MLN cells. After addition of the cells, the columns were 
incubated at 37 ºC for 1 hour and cells were eluted through a 22-gage needle at 1 drop per second. Collected 
cells were centrifuged at 1000 rpm for 10 min and resuspended at 2 x 106/ml in complete medium. The 
recovered cells were analyzed by flow cytometry to determine the percentage of CD3+ T cells in the preparation 
(> 90 %). For antigen-specific responses, T cells were added to control and antigen-pulsed APCs at a ratio of 
1:1 in flat bottom plates (Costar 3595).  
Proliferation/Cytokine Secretion by LUMINEX 100 technology 
Following 72 hour T cell/APC culture, 100 µl of cell supernatants were collected for cytokine analysis by the 
Luminex 100 technology and 100 µl of fresh complete medium was added back to cells. Cells were then pulsed 
with 10 µl of 50 µCi/ml 3H-thymidine for seven hours prior to harvesting. Incorporation of 3H-thymidine was 
quantified by a scintillation counter.  
 
Colonic Explants 
Colons were fileted open and 3 mm biopsy punches were extracted and placed into 96 well flat bottom plates 
(Costar 3595) in 200 µl complete RPMI 1640, 1X (Cellgro) plus 50 µg/ml gentamycin and 2X penicillin-
streptomycin per well per punch. Three punches were biopsied from each mouse. Cultures were incubated at 37 
ºC for 48 hours prior to recovery of supernatants and cytokine analysis.  
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Statistical Analysis 
 
Data is displayed as mean +/- SEM. Non-parametric group comparisons were analyzed by Kruskal-Wallis tests. 
Parametric group comparisons were analyzed by analysis of variance (ANOVA). Pairwise group comparisons 
having equal variances were analyzed using t-tests. 
 
Results & Discussion 
 
Dual treatment of H.bilis colonization and DSS administration increased disease severity 
In order to investigate the pathogenesis of IBD, a multiple hit model of colitis was developed. IBD is 
characterized by periods of quiescence interspersed by periods of active, chronic inflammation. To determine if 
an environmental insult could induce active inflammation following colonization with a novel organism, DSS 
was utilized. As a measure of an environmental/inflammatory trigger to induce active inflammation, a low dose 
of DSS was desired to expose lamina propria cells to luminal contents. Defined flora mice (C3H:HeN:Tac) 
were used for these experiments to assess antigen specific responses to the enteric flora in the development of 
IBD. To define a low dose of DSS to engage mild inflammatory responses, titration experiments were 
performed by administration of DSS that would not induce lesions and graded doses of DSS were added to 
drinking water for five days, followed by four days of restitution (Fig 1). A dose of 1.5% DSS was chosen for 
the multiple-hit model in DF mice that did not cause overt cecal or colonic damage, yet resulted in mild 
histological inflammatory scores in the colon, including macrophage and polymorphonuclear cell infiltrate (data 
not shown).  
 
Defined-flora C3H:HeN:Tac mice bearing ASF were colonized with H.bilis for 12 weeks. At which time they 
were exposed to a low dose (1.5%) of DSS in drinking water for five days immediately preceding four days of 
restitution. Mice were euthanized and tissues collected. Mice that received the dual treatment of H. bilis 
colonization and DSS administration had significantly greater (p < .05) cecal scores and shorter colon lengths 
compared to any other treatment group, indicating that the combined treatments exacerbated the observed colitis 
(Fig 2 & 3).  
 
To further investigate lesions of treated mice, proximal colon sections were prepared for histological analysis. 
In sections of colon from mice that were colonized with H. bilis and treated with DSS there were severe 
changes characterized by macrophage infiltration, ulceration, and marked mucosal hyperplasia (Fig 4B). 
Lesions in colonic epithelium tended to be multifocal in nature and in some sections, inflammation extended 
deeply into the tunica muscularis. In comparison to DSS treatment alone, H. bilis colonization with DSS 
treatment resulted in greater colonic scores (p< 0.05) than that for any other group, implicating the detrimental 
attributes of H. bilis colonization, prior to DSS treatment. 
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H. bilis Colonization Results in Antigen-specific Responses to Resident Flora 
 
Broken immune tolerance to normal flora bacterial components in patients with IBD has been manifested by 
increased serum IgG to (44-46). Previous experiments demonstrated the induction of serum responses to 
antigens derived from members of the altered Schaedler flora (ASF) at 3, 6, and 10 weeks after colonization 
with H. bilis (47). To determine if serum specific antibody responses to enteric flora antigens plateau after 12 
weeks similar to lesion severity, serum was assessed for IgG2a antibodies via ELISA. Following 3, 12, and 20 
weeks of H. bilis colonization serum was collected and assessed for IgG2a reactivity to each ASF antigen. H. 
bilis colonized mice had elevated IgG2a antibodies to ASF 356, 360, 361, 457, 492, 500, 502, and H. bilis WCS 
antigens compared to non-colonized controls, suggesting a loss of tolerance to the microbiota and an increase in 
Th1 immune reactivity (Fig 5). Responses to Clostridium spp (ASF 356 and 502) were elevated and have been 
associated with Cluster XIV flagellin antigens. These results support findings from Elson and colleagues that 
colitic mice and CD patients have elevated serological responses to flagellin proteins from the commensal flora 
(48, 49). This suggests that H. bilis colonization results in a Th1 mediated breach in tolerance to the enteric 
flora. To further assess the increased IgG2a responses to the flora, western blots were performed using WCS of 
ASF antigens loaded on SDS-PAGE gels and blotted with serum from H. bilis colonized mice at 3, 12, and 20 
weeks (Fig 6). Immunoblot analysis demonstrated that the number of antigens recognized by serum antibodies 
increased in number and intensity following H. bilis-colonization over time. Furthermore, molecular weight 
bands at 55-60 kb may correspond to flagellin recombinant protein, but further experiments needs to be 
performed (49). IgG1 responses were weak to non-detectable (data not shown). These results may be indicative 
of epitope spreading.  
 
CD4 T cells have been implicated in the development of IBD (50). The development of antibody reactivity to 
H. bilis antigen and the increase over time to antigens of the commensal flora prompted us to investigate if H. 
bilis increased the T cell reactivity to the flora.  MLN T cells were cultured with APCs that had been primed 
overnight with antigens from the enteric flora (ASF) or no antigen. T cells from H. bilis colonized animals, but 
not from control animals proliferated to the enteric flora indicating that colonization with a bacterial 
provocateur can induce antigen-specific immune reactivity to the enteric flora that may contribute to 
susceptibility to an environmental trigger (Fig 7).   
 
Mucosal Inflammatory Cytokine Expression is Elevated in the H. bilis Dual Group  
IL-17 has been associated with multiple human autoimmune disorders and IBD (51-54). Likewise, IL-17A has 
been shown to mediate intestinal inflammation in H. hepaticus infected mice administered anti-IL-10R 
monoclonal antibodies (55). To determine if there is an association between the induced antigen-specific 
reactivity to the commensal flora and IL-17A in the mucosa, we assessed IL-17A gene expression in proximal 
colon tissue and IL-17A protein in colonic explants following H. bilis colonization and DSS treatment. H. bilis 
colonized mice that were DSS treated induced IL-17A mRNA expression in proximal colonic tissue that was 
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associated with  elevated protein for IL-17A from colonic explants (Fig 8). This finding indicates that IL-17A 
may modulate inflammation in the dually treated group. The induction of IgG2a serum responses indicated an 
elevated Th1 response following H. bilis colonization, therefore, we assessed expression of inflammatory 
cytokines locally in the proximal colon. IFN-γ (     Α) and TNF-α (Fig 9B) RNA expression in the dual 
treatment group was elevated compared to control groups (Fig 9). This suggests that H. bilis colonization is 
changing the mucosal environment such that a low dose DSS insult results in inflammation. Other groups have 
reported the detrimental effects of IFN-γ and TNF-α on epithelial cells in vitro (56, 57). Although we cannot 
directly say that these inflammatory cells affected the colonic epithelium, histological analysis revealed that 
enterocytes along the luminal surface of the colonic glands within the H. bilis dual treatment groups presented 
with attenuated low cuboidal morphology compared to the tall columnar adjacent enterocytes (Fig 9C). The 
changes in cellular morphology were indicative of acute cellular injury that might precede enterocyte death and 
loss. The glands associated with these cellular changes were hypercellular and lacked goblet cells indicating a 
hyperplastic response.  
 
Mucosal Foxp3 Elevated in H. bilis Dual Treatment Group 
Regulatory T cells actively suppress the proliferation and cytokine production of effector T cells. To further 
define the mechanism behind the increase in immunological responses to the enteric flora, we hypothesized that 
H. bilis may be altering T regulatory cell function, resulting in less regulation and increased host 
responsiveness. Foxp3 is a transcription factor for regulatory T cell development, maintenance, and function 
and mice that do not express Foxp3 develop a fatal autoimmune disease characterized by hyperresponsive CD4+ 
T cells (58). H. bilis colonization mice treated with DSS displayed elevated levels of Foxp3 expression in the 
proximal colon at three and 12 weeks post-infection (Fig 10). Increased T regulatory cells at the site of infection 
may be beneficial for the host to prevent overt inflammation, however, this may also be beneficial for the 
pathogen, to sustain colonization.  
 
DSS Treatment and H. bilis Colonization Increased Bacterial Invasion Within Colonic Tissue 
To confirm H. bilis colonization prior to DSS administration, fecal samples were collected and DNA was 
extracted for PCR analysis by using primers for the 16s ribosomal RNA. To determine if the H. bilis and DSS 
dual group was more severe due to H. bilis attachment to the epithelium, thus increasing its pathogenicity, 
colonic samples were harvested and fixed in gluteraldehyde for analysis by electron microscopy. H. bilis 
organisms were found in the lumen in close proximity to the mucosa (Fig 11-A), within the interepithelium (Fig 
11B-C), and occasionally within the colonic tissues (Fig 11D). The results of the PCR analysis and the electron 
photomicrographs indicated that H. bilis did not transiently colonize, but persisted. The close proximity of the 
organism within the gland or in the epithelial cells suggests an increased probability of APC sampling and 
bacterial translocation, contributing to disruption of mucosal homeostasis.  
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Conclusion 
The human resident flora in the gastrointestinal tract contains 100 times more microbial genes than the 
human genome (59). Although this mutualistic relationship with our microbiome aids in metabolizing of 
nutrients and benefits epithelial health and immunity, consequences of a break-down in tolerance can be 
detrimental. A chronic inflammatory response to the enteric flora has been associated with IBD, although it has 
not been clearly identified if this response develops prior to clinical IBD or is a consequence of IBD (9, 43, 49, 
60-62). Therefore, development of a model that is capable of assessing the kinetics of antigen-specific 
responses and the importance of these immune responses against individual members of the microbiota will aid 
in the understanding of the mechanisms regulating the development of IBD. The pathogenesis of IBD has not 
been shown to be caused by a single organism, but instead there are multiple possibilities that likely contribute 
to IBD susceptibility and severity. Previous results from this laboratory indicate that H. bilis colonization of DF 
immunocompetent mice results in a multitude of upregulated genes involving the immune response, proteolysis, 
glycoprotein synthesis and protein metabolism and significantly downregulated genes including several 
involved in fatty acid metabolism, lipid metabolism and detoxification (Zhiping Liu-submitted for publication). 
Although H. bilis did not induce overt mucosal inflammation during the course of these studies, we hypothesize 
that the disruption in the microbial ecology by the introduction of a novel organism predisposes the host to react 
more vigorously to exposure to an environmental trigger/stressor at a later time. In contrast to bacteria that 
transiently colonize the GI tract, persistent colonization with a bacterial provocateur would be especially 
problematic for the susceptible host. Using defined-flora mice to develop a provocateur-trigger model of IBD 
(two hit model) allows for the chronological investigation of changes in antigen-specific immunity, and the 
mechanisms affecting the onset of clinical signs that are not simply the consequence of inflammation following 
the onset of overt clinical signs associated with disease. Another advantage of this provocateur-trigger model is 
the ability to assess these responses in immune competent mice. Understanding the initial immune responses 
following the introduction of an environmental trigger (ex: DSS) may reveal evidence as to the mechanisms 
associated with the onset of disease and allow the rational design of strategies that will prevent or control IBD.   
Following colonization of DF mice with H. bilis for 12 weeks and subsequent exposure to a low dose 
of DSS, the magnitude of gross and histological lesions are significantly more severe than those of mice treated 
solely with DSS or colonized with H. bilis. Likewise, the combined treatments of H. bilis colonization and DSS 
administration resulted in an increase in cecal score and decreased colon length compared to controls, DSS 
alone, and H. bilis alone. The magnitude of these macroscopic changes was associated with the severity of the 
histological changes (infiltration of mononuclear cells, increased hyperplasia, ulceration and epithelial erosion) 
within the colonic mucosa of mice in the dual treated group.  
A break in tolerance to antigens derived from the enteric flora is thought to occur during IBD episodes 
(60). Loss of tolerance has been manifested by increased serum IgG directed against bacterial components in 
patients with IBD (44-46). Assessment of serum antibody responses in the present study indicated that H. bilis 
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colonization increased IgG2a production to the majority of the ASF organisms by 12 weeks post-colonization 
(Fig 5). The Clostridium subphylum is the most represented bacteria in human intestinal mucosa and IgG serum 
antibodies to clostridial flagellin (Cbir) are increased in patients with IBD (46, 62). In the absence of DSS 
treatment, mice colonized with H. bilis presented with greater IgG2a response to ASF 356 and 502 Clostridium 
species, suggesting that these responses are similar to those observed in human IBD patients and C3HheJBir 
mice (62). In addition, this observation suggests that the enhanced susceptibility to low dose DSS-induced 
colitis is dependent upon or associated with the induction of a Th1 response to members of the enteric flora.  
Proinflammatory cytokines can be detrimental to the health of epithelial cells. Specifically, IFN-γ and 
TNF-α have been shown to change the cellular morphology of, effect barrier function of, and reduce chloride 
secretion by epithelial cells (56). These cytokines have also been shown to increase the production of reactive 
oxygen species (ROS) in colonic epithelial cells (57).  Dual treatments of H. bilis colonization and DSS 
administration result in a 3.2 fold increase of mucosal IFN-γ expression and a 1.5 fold increase in TNF-α 
expression in the proximal colon compared to control groups. To determine if the proinflammatory cytokines 
induced within the colonic mucosa of mice dually treated with H. bilis and DSS correlated with changes in 
epithelial integrity and morphology, proximal colon sections were stained with hematoxylin and eosin (H & E). 
The colonic epithelium from mice dually treated with H. bilis and DSS presented a flattened epithelial  
morphology and increased numbers of infiltrating macrophages/neutrophils within the lamina propria that may 
have contributed to mucosal hyperplasia.   
The discovery of Th17 cells expanded previous concepts proposing that Th1, Th2, and T regulatory 
lineages were the sole effector cells for the immune response. The development of Th17 cells in murine tissues 
requires TGF-β and IL-6, although maintenance requires IL-23 (63-67). Many articles have addressed the 
inflammatory characteristics of IL-17 following the onset of autoimmune diseases like EAE and IBD (51-54, 
66, 68). For example, IBD patients have elevated IL-17A expression in colonic mucosa (51) and in mice, 
clinical signs of TNBS-induced colitis including weight loss, IL-6 production, myeloperoxidase activity, and 
local macrophage inflammatory protein-2 induction are ameliorated in IL-17R knockouts (69). The induction of 
IL-17 responses in immune competent animals following the onset of colitis has not been previously 
demonstrated. H. bilis colonized mice treated with DSS had elevated mucosal expression of IL-17A-specific 
mRNA and increased amounts of IL-17 protein was secreted from colonic explants. This finding supports 
previous observations that local synthesis of IL-17 may contribute to chronic IBD episodes.  In addition, 
exposure of DF mice to DSS treatment resulted in the increased secretion of IL-6 from colonic explants. We 
hypothesize that H. bilis colonization results in the recruitment of Tregs that secrete TGF-β. The combination of 
TGF-β and the proinflammatory cytokine IL-6 ultimately results in effector Th 17 cells (64).  
We hypothesized that the mechanism of increasing antigen-specific immune reactivity to the 
commensal microbiota following 3, 12, and 20 weeks H. bilis colonization was due to decreased T regulatory 
cells in the local environment. However, Foxp3 expression in the proximal colon indicated an increased 
expression in the dual group compared to either treatment group alone (data not shown). Based on the increase 
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in Foxp3 mRNA expression in the colonic mucosa, we speculate that H. bilis colonization resulted in the 
recruitment of Treg cells to the lamina propria of the colon to downregulate adaptive immune responses to the 
ASF and /or H. bilis; however, additional experiments will be required to confirm this. A consequence of 
recruitment and activation of Treg cells would be to sustain H. bilis colonization by dampening adaptive 
immunity. Other pathogens including H. pylori and Bordetella pertussis have been shown to recruit T regs to 
sustain colonization (70, 71). Patients with CD have also been shown to have increased Foxp3+CD4+ cells in the 
intestinal mucosa that retain suppressive functions ex vivo (72). Interestingly, as immune reactivity increases 
over time including elevated serum antibody responses, Foxp3 expression within the mucosa of the H. bilis 
colonized mice decreases. Although we cannot say that this is directly due to a decrease in Foxp3, we speculate 
that Treg cells hinder the resolution of the infection. In addition, other regulatory mechanisms may potentially 
be in place to prevent overt inflammation. Alternatively, the increased reactivity to the flora over time may 
suggest that the T regulatory cells are converting into Th17 cells that may be modulating damage. Following H. 
bilis colonization, preliminary data (not shown) indicated that the presence of IL-17-specific mRNA in the 
colonic mucosa increased over time. Other groups have shown that T regulatory cells convert into IL-17 
producing cells when cultured with IL-6 (73).  
Following the colonization with a bacterial provocateur, immune competent mice colonized with a 
defined flora of eight bacteria were shown to be predisposed to colitis and were characterized as having 
upregulated immune reactivity to antigens derived from the resident flora. The newly induced immune 
reactivity to the commensal flora alone was not deleterious to the health of H. bilis colonized mice as these mice 
did not develop overt inflammation; however, in the context of an inflammatory insult, the onset of IBD is 
triggered. Utilizing an experimental model that employed a provocation-trigger treatment regimen resulted in 
the upregulation of Th1 and Th17 immune responses that may contribute to the pathologenicity of disease. To 
confirm that the IL-17 secreting and antigen-specific proliferating CD4+ T cells are pathogenic, future 
experiments involve the transfer of either IFN-γ and IL-17 secreting mesenteric lymph node CD4+ T cells or 
IFN-γ and IL-17 secreting lamina propria lymphocytes (LPLs) from H. bilis colonized animals into naïve, 
defined flora mice (Helicobacter free).  If the mild colitic insult imparted by low dose DSS is sufficient to 
induce disease, it could be inferred that the ability of the transferred LPLs or CD4+ from H. bilis colonized mice 
will predispose the host to DSS sensitivity mediated by immune activation by antigens from the resident 
bacterial flora. In conclusion, H. bilis colonization of DF mice resulted in immune reactivity to the commensal 
flora that increased susceptibility to DSS-induced colitis. These results signify that humans colonized with a 
novel provocateur are predisposed to an environmental insult later in life.  
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Figure 1. 1.5% DSS induces minimal clinical signs of IBD in defined flora mice. Defined flora mice 
were administered graded doses of DSS in drinking water for five days preceding four days of restitution. 
Measurement of parameters including percent weight change from day 0 (A), cecal score (B), and colon length 
(C) indicated that 1.5% DSS induced minimal clinical signs of colitis. Ceca were blindly scored using a scale 
from 0 (healthy) to 4 (severe macroscopic lesions). Data is presented as the mean + SEM. Statistical significance 
indicated is p < .05*, p < .01 **. n =5 per treatment group. Representative of two experiments.  
 
 
 
Figure 2. Dual treatment group displayed increased macroscopic lesions of 
colitis. Defined flora mice were colonized with H. bilis for 12 weeks and/or 
treated with 1.5% DSS in drinking water for five days followed by four days 
restitution. Gross scores including cecal score and colon length were measured. 
The photographs depict representative ceca and colons from each of the four 
treatment groups.  It should be noted that the colons from the dual treatment 
group displayed decreased cecal/colonic contents, thickened and shortened 
colon length (numbers on upper right corner), cecal atrophy, blunting and 
presence of blood.  
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Figure 3. H. bilis colonization results in increased susceptibility to DSS-induced colitis. Defined flora 
mice were colonized with H. bilis for 12 weeks and/or administered 1.5 % DSS. Ceca were blindly scored 
as previously described using a scale from 0 (healthy) to 4 (severe macroscopic lesions) (A) and colon 
length was measured (B). Data is presented as the mean + SEM. Statistical significance indicated is p < 
.05*, p < .01**. n = 5 to 10 mice per treatment. Results are representative of eight independent experiments 
following H. bilis colonization.  
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Figure 4. H. bilis and DSS dual treatments increased colonic disease scores. Following 12 weeks post-
infection with H. bilis or DSS treatments mice were euthanized, proximal colon was histologically scored for 
inflammation and erosion parameters as described in Materials and Methods (A). Hematoxylin and eosin 
staining of proximal colon depicting infiltration of mononuclear cells, crypt hyperplasia, with loss of goblet cell 
differentiation and gland dropout in H. bilis and DSS treated group (E) compared to control (B), DSS alone (D), 
or H. bilis colonized only (C). n = 5 per treatment group. Data is presented as the mean + SEM. Statistical 
significance indicated is p < .05*. Representative of eight independent experiments.  
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Figure 5. H. bilis colonization increased IgG2a antibody response over time to H. 
bilis & ASF antigens. Serum samples from H. bilis colonized mice and non-
colonized mice were assessed by ELISA for reactivity to whole cell lysates derived 
from enteric flora whole cell lysates of the resident microbiota (ASF 356: Clostridium 
spp. Cluster XIV; ASF 360: L. acidophilus; ASF 361: L. murinus; ASF 457: M 
schaedleri; ASF 492: E. plexicaudatum; ASF 500: Low-G+C-content gram-positive; 
ASF 502: Clostridium spp. Cluster XIV; ASF 519: B. distasonis), H. bilis, and S. 
epidermidis (S.epi). Absorbance (OD) was measured spectrophotometrically (405 
nm). Data is presented as the mean + SEM of the optical density (OD) for each 
treatment group of mice. n = 5 mice per treatment group, representative of 3 
independent experiments. Differences in the serum antibody response to each of the 
individual ASF antigens is indicated by the presence of different letter.  p ≤ 0.05. 
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Figure 6. H. bilis induced broader IgG2a serum antibody responses to commensal microbiota over time. 
Evaluation of serum antibody reactivity to whole cell lysates of the ASF was performed by immunoblot analysis. Panel 
A: serum samples from control defined flora (DF) mice; Panel B: serum from DF 3 weeks postcolonization with H. bilis; 
Panel C: serum from DF mice 12 weeks postcolonization with H. bilis; Panel D: serum from DF mice 20 weeks 
postcolonization with H. bilis. Lane 1: Precision Plus protein standards; Lanes 2 – 9: altered Schaedler flora (ASF) 
antigens (356: Clostridium spp. Cluster XIV; 360: L. acidophilus; 361: L. murinus; 457: M. schaedler;i 492: E. 
plexicaudatum; 500: Low-G+C-content gram-positive; 502: Clostridium spp. Cluster XIV; 519: B. distasonis); lane 10: 
S. epidermidis; Lane 11: H. bilis. Each lane was loaded with 7 µg of total protein from the specified bacterial lysates, 
separated electrophoretically using 12% tris-glycine gels, and immunoblots blots were developed using pooled serum 
samples from 5 mice per treatment group as described in Materials and Methods. 
 
 
 
 
 
  1     2      3    4     5     6      7     8     9   10   11      
1     2      3    4    5   6     7     8     9   10   11       1     2      3    4      5     6    7    8     9    10   11    
       1     2     3   4    5    6     7    8    9  10  11     
A 
C D 
B 
150  
75  
250  
100  
50  
37 
25 
20 
15 
150  
75  
250  
100  
50  
37 
25 
20 
15 
150  
75  
250  
100  
50  
37 
25 
20 
15 
150  
75  
250  
100  
50  
37 
25 
20 
15 
 48 
Controls H. bilis Colonized
0
2
4
6
8
10
12
14
APC (no antigen)
APC (pooled ASF)
Treatments
*
*
*
 
Figure 7. H. bilis colonization induces antigen specific T cell proliferation. MLN T cells 
were enriched from mice colonized with H. bilis for 12 weeks and stimulated with splenic 
antigen presenting cells that had been stimulated with pooled ASF antigens at 1:1 ratio of 
APC: T cells for 72 hours as described in Materials and Methods. Proliferation was assessed 
via 3H-thymidine incorporation. Data is presented as the mean + SEM. Stimulation index (SI) 
was calculated by dividing counts per minute of stimulated cultures by control values (APC no 
antigen). n = 3 per treatment group. * p ≤ .06, ** p ≤ .02. Results are representative of three 
independent experiments. 
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Figure 8. Mucosal IL-17A is Elevated in H. bilis Dual Treatment Group. (A) Real-time RT-PCR 
analysis for IL-17A-specific mRNA and (B) analysis of supernatants from ex vivo colon cultures for IL-17A 
protein secretion.  Samples were collected from defined flora mice colonized with H. bilis and/or treated 
with 1.5% DSS. RT-PCR data is displayed as fold changed normalized to GAPDH. Data is presented as the 
mean + SEM. Statistical significance between groups is indicated by different letters. Data are representative 
of at least two independent experiments. n = 5 mice per treatment group. 
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Figure 9. Mucosal Proinflammatory Expression 
Elevated in Dual Treatment Group. Real-time RT-PCR 
analysis of IFN-γ (A) or TNF-α (B) in the proximal colon 
following colonization of H. bilis colonized defined flora mice 
for 12 weeks and/or 1.5% DSS treatment. (C) Hematoxylin and 
eosin staining of proximal colon following dual treatments of H. 
bilis colonization and DSS administration illustrates attenuation 
of the outer enterocytes of the glands (arrow). Data is presented 
as the mean + SEM. n = 5 mice per treatment group. Data are 
representative of two independent experiments. 
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Figure 10. Mucosal Foxp3 expression decreased over time. Real-
time RT-PCR Foxp3 analysis of proximal colon tissue following H. 
bilis colonization for 3, 12 or 20 weeks. Data is displayed as fold 
change after normalization to GAPDH. Data is presented as the mean + 
SEM. Data are representative of at least two independent experiments. 
n = 5 mice per treatment group.  
 
 
 
 
 
 
 
 
 
 51 
  
  
Figure 11. Colonic localization of H. bilis following colonization of  defined flora mice. Electron 
microscopic analysis of proximal colon from defined flora mice colonized with H. bilis for 12 weeks and 
treated with 1.5% DSS. H. bilis was observed in the lumen (A), within the glands (B-C) (the inset in panel 
B is shown in C) and within the epithelial cells (D). 
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Abstract 
While the etiology of inflammatory bowel disease (IBD) is unknown, host genetics, the intestinal microbiota, 
and aberrant immune responses have been implicated as contributing factors. However, the initial provocation 
and subsequent inflammatory trigger(s) have yet to be discovered. Although there is evidence that IBD patients 
respond immunologically to antigens derived from their enteric microbiota, no specific microbial agent has 
been identified as the sole initiator/provocateur of IBD. Our laboratory has previously shown that colonization 
of defined-flora (DF) (i.e., gnotobiotic) mice with Helicobacter bilis induced immune reactivity to the 
commensal enteric flora. It was hypothesized that the nature of the provocateur (i.e., virulence potential) 
influences the manner in which the host reacts to its microflora, thus, modulating the susceptibility to 
subsequent colitic insults (i.e., triggers). To test this hypothesis, groups of 6-8 week old, DF C3H/HeN:Tac 
mice bearing the altered Schaedler flora (ASF) were colonized with a non-pathogenic strain of Escherichia coli. 
As a measure of susceptibility to mucosal inflammation, these mice were treated for five days with a low dose 
(1.5 %) or high dose (2.5%) of dextran sulfate sodium (DSS) in their drinking water at 3 or 12 weeks post-
colonization with E. coli. Mice were euthanized 6 days after cessation of the DSS treatment and evaluated for 
gross and histological lesions, cytokine-specific mRNA expression, humoral and cell-mediated immune 
responses. In contrast to DF mice colonized with H. bilis, colonization of DF mice with E. coli did not 
significantly increase the susceptibility to low-dose DSS; however, the susceptibility to typhlocolitis following 
exposure to  high-dose DSS was markedly increased as evidenced by the induction of macroscopic and 
histological cecal lesion scores. Similar to control mice, E. coli colonization of the DF mice alone induced no 
macroscopic lesions. Interestingly, DF mice colonized with E. coli, developed ASF antigen-specific CD4+ T 
cell proliferative responses following in vitro stimulation that was not dependent upon DSS exposure. The 
treatment of E. coli colonized mice with 2.5 % DSS resulted in the induction of ASF-antigen-specific IL-17A 
secretion from mesenteric lymph node CD4+ T cells and cecal mucosal expression of IL-17A-specific mRNA. 
Depending on the severity of a subsequent inflammatory insult, these studies demonstrated that introduction of 
a non-pathogenic, commensal strain of E. coli  could also serve as a mucosal provocateur and that its impact on 
 59 
the colonic mucosal homeostasis (e.g., gene expression, aberrant immunity) is a critical factor that predisposes 
to the onset of IBD. 
 
 
Introduction 
The human gastrointestinal (GI) tract is the organ with the largest surface area (100 m2) in the body 
and must accommodate the digestion and absorption of 500 kg of food per year. The GI tract also harbors a 
diverse microbiota (1013 organisms/gram contents) that aid in immune system development/maturation and 
nutrient metabolism (1). However, a GI tract function that perhaps is less well considered is the role that the 
intestinal epithelium serves as the physical interface between the host and the environmental components 
located in the GI tract lumen. In this regard, the GI tract serves as a barrier for environmental dangers like 
pathogenic bacteria that attempt too colonize and invade the epithelial layer. In order to prevent the onset of 
intestinal inflammation, the GI tract has developed regulatory mechanisms that function to maintain mucosal 
health and immunological tolerance in the face of the constant borage of food and microbial components while 
maintaining the beneficial relationship of commensal bacteria. Inflammatory bowel disease (IBD) is a chronic 
inflammation of the GI tract that is hypothesized to result from the immune system attacking the enteric flora. 
Previous experiments from this laboratory indicated that development of DSS-induced colitis in immune 
competent, defined flora (DF) mice required the prior colonization with a bacterial provocateur, Helicobacter 
bilis. H. bilis is a mildly pathogenic, Gram-negative, motile, microaerophilic bacteria that has been associated 
with IBD-like lesions in immunocompromised mice (2-4). Colonization of DF mice with H. bilis resulted in 
disruption of mucosal homeostasis as evidenced by changes in profile of mucosal gene expression and the 
induction of antigen-specific cellular and humoral immune responses to the commensal flora. Additionally, H. 
bilis-colonized DF mice developed typhlocolitis following exposure to an otherwise innocuous low dose of DSS 
that was characterized by increased mucosal expression of IFN-γ− and IL-17-specific mRNA. Because the 
development of IBD is closely associated with the presence of a complex microbiota and IBD induction has not 
been ascribed to a single organism, it was hypothesized that the nature of the provocateur (virulence attributes) 
in conjunction with a downstream environmental insult/trigger (e.g., DSS) determines the severity of the 
resultant inflammatory response.  When considering a multi-hit model of IBD, it will be critical to evaluate the 
range of host responses to different provocateurs in the context of subsequent colitic insults or triggers.  To 
determine if susceptibility to DSS-induced colitis resulted simply as a result of colonization of the GI tract with 
a novel organism, DF mice were colonized with a commensal strain of Escherichia coli. These studies support 
previous observations that colonization of DF mice with a novel organism (H. bilis or E. coli) disrupts mucosal 
homeostasis and increases their susceptibility to a mild to moderate colitic insult/trigger.  
 
 
 
 60 
Materials & Methods 
Animals  
Six- to eight-week old C3H/HeN:Tac mice naturally colonized with a defined flora  (altered  Schaedler’s  flora: 
ASF 356: Clostridium spp. Cluster XIV; ASF 360: Lactobacillus acidophilus; ASF 361: Lactobacillus murinus; 
ASF 457: Mucispirillum schaedleri; ASF 492: Eubacterium plexicaudatum; ASF 500: Low-G+C-content gram-
positive; ASF 502: Clostridium spp. Cluster XIV; ASF 519: Bacteroides distasonis) were originally obtained 
from Taconic Farms (Albany, NY) and subsequently bred and maintainied in gnotobiotic isolators at Iowa State 
University. All mice were certified free of E. coli spp prior to use in these studies. Following colonization with 
E. coli all animals were housed (2-4 mice/cage) in gnotobiotic  isolators. Mice were fed an irradiated rodent diet 
and autoclaved water. All experiments were approved by Iowa State University Animal Care Committee.  
 
Experimental Design  
Defined flora mice of mixed gender were separated into 4 groups: 1) Non-colonized, 2) Non-colonized + DSS, 
3) E. coli colonized alone, and 4) E. coli colonized + DSS. Groups three and four were inoculated by oral 
gavage with > 2 x 107 E. coli CFU in 0.3 ml of Brucella broth three times over a 3-day period. E. coli infection 
status was confirmed by fecal cultures on EMB agar plates. E. coli was evaluated for virulence factors (cvaC, 
iron, ompTp, hlyF, etsA, iss, aerJ, ireA, papC, cdtA, cdtC, cdtB) by PCR. Three-12 weeks postinfection  (PI), 
groups two and four and six received either low (1.5%) or high (2.5%) DSS (MW=36-50kD, ICN) in deionized 
drinking water for five-six days, followed by three-four days with regular sterile water. Groups one and three 
received sterile water only throughout the entire experiment. Immediately following the restitution period from 
DSS, mice were euthanized with CO2 and necropsied. Tissue samples were fixed in 10% buffered formalin and 
submitted for routine histopathological evaluation. Mesenteric lymph nodes (MLN) were collected and 
negatively sorted for CD4 T cells by MACS magnetic beads and MS separation columns (Miltenyi Biotech). In 
order to generate antigen presenting cells (APCs), spleen cells were harvested from SPF C3H mice one day 
prior to necropsy and incubated with ASF antigens (200 µg/ml) overnight. Following mitomycin C treatment 
(Fisher)(see Chapter #2) APCs were inoculated into microtiter plates along with CD4 T cells at a 1:1 ratio and 
assigned to one of seven treatments: APC-NS (no stimulant), APC-Pool (pooled ASF antigens), APC- 457/519, 
APC-492/360/361), APC-356/500/519, APC-Ec or APC-Se (E. coli or Staphylococcus epidermidis, 
respectively), or anti-CD3/28 and incubated for 72 hours. Prior to the addition of 3H-thymidine, an aliquot of the 
culture supernatant was collected and analyzed by a multiplex fluorescent bead assay for the following 
cytokines: IL-2, IL-6, IL-10, IL-12(p40), IL-17, IFN-γ, and TNF-α. In addition, samples were assessed for 
antigen-specific serum antibody responses and tissue from the proximal colon was analyzed by quantitative RT-
PCR for gene expression.  
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Preparation of Bacterial Antigens 
Each member of the altered Schaedler’s flora (ASF360, ASF361, ASF356, ASF457, ASF492, ASF500, 
ASF502, and ASF519) was grown in bacteriological medium and cultured at 37ºC for five to seven days under 
anaerobic conditions. Cells will be grown in either reinforced clostridium medium (RCM) supplemented with 5 
% calf serum (ASF360, ASF361, ASF 356, ASF 502, and ASF519) or Schaedler’s broth supplemented with 5 
% sheep serum (ASF457, ASF492, and ASF500). Because many of these organisms are extremely oxygen 
sensitive (EOS), all inoculations were performed in an anaerobic chamber (Bactron). Commensal E. coli was 
isolated from a conventional flora-bearing C3H mouse and grown aerobically in Brucella broth at 37ºC for 
approximately 4 - 7 hours (McFarland scale #6, ca 5 x 108) and tested for purity prior to inoculation into DF 
mice. Cells were harvested from the broth by centrifugation, washed in buffer, and lyophilized. Bacterial 
antigens (e.g. all eight ASF strains) used for in ELISA or for in vitro stimulation of lymphocyte cultures were 
prepared from the lyophilized cells. The cell suspensions were placed on ice and sonicated for 5 minutes to 
prepare whole cell sonicates (WCS). WCS was sterilized by UV light irradiation and stored at –20 °C until use. 
Sterility of each individual WCS was confirmed bacteriologically.   
 
Gene Expression via Real Time RT-PCR  
Total RNA was extracted from 20 mg of proximal colon by RNAeasy Mini Kit (Qiagen). The RNA samples 
were quantified by ND-1000 spectrophotometer (Nanodrop technologies) and treated with TURBO DNA-free 
DNase (Ambion) to eliminate genomic DNA contamination. RNA was reverse transcribed into cDNA by 
SuperScript™ III First-Strand Synthesis System (Invitrogen, San Diego, CA). cDNA was amplified using 
Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen). The following PCR conditions were used: 95°C 
for 10min followed by 40 cycles of amplification (95°C for 10 s, 56°C for 5 s, and 72°C for 10 s). Primers for 
GAPDH (forward primer: 5’- TCACCACCATGGAGAAGGC-3’, reverse primer: 5’-
GCTAAGCAGTTGGTGGTGCA-3’), IFN-γ (forward primer: 5’- TCAAGTGGCATAGATGTGGAAGAA-3’, 
reverse primer: 5’-TGGCTCTGCAGGATTTTCATG-3’), TNF-α (forward primer: 5’-
CATCTTCTCAAAATTCGAGTGACAA-3’, reverse primer: 5’-TGGGAGTAGACAAGGTACAACCC-3’) 
and IL-17A (forward primer: 5’-CTGAGAGCTGCCCCTTCACT-3’, reverse primer: 5'-
CCACACCCACCAGCATCTTC-3’) were used. The real-time quantitative PCR was performed using Applied 
Biosystems GeneAmp™ 5700 Sequence Detection System.  Standard curves for each gene were made using a 
series of cDNA dilutions. The relative mRNA quantity of each gene was normalized to GAPDH (5). 
 
Histopathology  
Sections of cecum and colon were fixed in 10% buffered formalin. The tissues were routinely processed, 
embedded in paraffin, sectioned at 5 µm and stained with hematoxylin and eosin. Tissues sections from each 
mouse were scored for severity of mucosal epithelial damage, glandular alterations, and magnitude/character of 
the lamina propria cellular infiltrate. Histological sections were evaluated blindly by J.M. Hostetter, Department 
of Veterinary Pathology, Iowa State University and the scores for individual parameters ranged from 0 (healthy) 
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to 5 (diseased) for both erosion and inflammation (6).  
 
Analysis of Antigen-Specific Serum Antibodies.   
Antigen-specific serum antibody responses were measured by enzyme linked immunosorbant assay (ELISA). 
Serum antibody levels in mice were determined by enzyme linked immunosorbant assay (ELISA). Briefly, 96-
well plates (Costar-3590) were coated with 100 µl/well of whole cell sonicate (WCS) at 10 µg/ml derived from 
the individual members of the altered Schaedler’s flora (ASF) and H. bilis diluted in PBS (pH 7.4) overnight at 
4ºC. Plates were washed three times in PBS/.05%Tween 20 and blocked with 280 µl/well 2% gelatin diluted in 
PBS/.05%Tween 20/2% FBS for two hours at room temperature. Plates were washed three more times with 
PBS/.05%Tween 20 prior to addition of 100 µl/well serum samples diluted 1:200 in PBS/Tween/2% FBS 
overnight at 4ºC. Plates were washed five times with PBS/.05%Tween 20. Then, 100 µl of 1:2000 diluted 
alkaline phosphatase -conjugated goat anti-mouse IgG (H&L), IgG1 or IgG2a (Southern Biotechnology) in 
PBS/Tween/2% FBS was added per well and incubated for 2 hours at room temperature. Prior to washing five 
times with PBS/Tween 20 (.05%), wells were developed for a colorimetric reaction using 100 µl of p- 
nitrophenyl phosphate (Sigma 104) (1 mg/ml) at room temperature. Absorbance was measured using an ELISA 
reader (405 nm). 
 
Preparation of Antigen Presenting Cells (APCs)/Mitomycin C Treatment 
Spleens were recovered from three adult C3H/HeOuJ mice and homogenized to prepare single cell suspensions 
in complete RPMI 1640, (Cellgro) containing 5% FBS, 1M HEPES, essential amino acids, non-essential amino 
acids, 1 mM sodium pyruvate, (2mM) L-glutamine, penicillin-streptomycin, 25 µg/ml gentamycin and 175 µl 2-
β-mercaptoethanol. APCs were pulsed with antigen using a method adapted from Cong et al (7). Two separate 
aliquots of 20 x 106 cells/5 ml were placed into two 15 ml tubes with 200 µg/ml (protein content) of combined 
ASF antigens added to one aliquot or media alone to the other aliquot and both were incubated overnight at 
37ºC. The APC preparations were then incubated in the presence of mitomycin C (50 µg/ml final concentration) 
at 37ºC for 30 to 45 minutes. The cell suspensions were washed five times using RPMI supplemented with 5% 
fetal calf serum (FCS) and antibiotics (8). 
 
Proliferation/Cytokine Secretion via LUMINEX 
T cell and APCs were cultured for 72 hrs, 100 µl of cell supernatants were collected for cytokine analysis by the 
Luminex 100 technology and 100 µl of fresh complete medium was added back to cells. The culture was then 
pulsed with 10 µl of 50 µCi/ml 3H-thymidine for seven hours prior to harvesting. Incorporation of 3H-thymidine 
was quantified by a scintillation counter.  
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Colonic Explant Supernatants 
Colonic tissues were fileted open and 3 mm biopsy punches were extracted and placed into 96 well flat bottom 
plates (Costar 3595) in 200 µl complete RPMI 1640, (Cellgro) plus 50 µg/ml gentamycin and 2X penicillin-
streptomycin per well per punch. Three punches were biopsied from each mouse. Cultures were incubated at 37 
ºC for 48 hours prior to recovery of supernatants and cytokine analysis.  
 
Statistical Analysis 
 
Data is displayed as mean + SEM. Non-parametric group comparisons were analyzed by Kruskal-Wallis tests. 
Parametric group comparisons were analyzed by analysis of variance (ANOVA). Pairwise group comparisons 
having equal variances were analyzed using t-tests. 
 
Results & Discussion  
 
Three week E. coli colonization of defined flora mice does not increase susceptibility to low-dose DSS-
induced colitis 
Prior experiments from this laboratory indicated that H. bilis colonization of DF mice resulted in antigen-
specific cellular and humoral responses to the commensal microbiota that was exacerbated by low-dose (1.5%) 
DSS and characterized by increased mucosal expression and protein secretion of proinflammatory cytokines. To 
determine if these responses were uniquely associated with H. bilis colonization, DF mice were colonized with 
a non-pathogenic, commensal strain of E. coli that was originally isolated from a conventional colony of C3H 
mice. Three weeks after E. coli colonization, mice were administered 1.5% DSS in their drinking water. After 
five days of exposure to 1.5 % DSS and four days of restitution on normal drinking water, mice were 
euthanized and evaluated for the presence of colitis. Ceca and colons were excised and scored for clinical signs 
of colitis. Mice that received the dual treatment of E. coli colonization and 1.5% DSS presented with similar 
cecal scores and colon lengths as control DF mice (Fig 1 and 2). These macroscopic observations were 
consistent with the histological scores (Fig 3) indicating that colonization with commensal E. coli did not 
predispose the DF mice for the development of colitis in response to 1.5% DSS.  
 
E. coli colonization enhanced CD4+ T cell proliferation to commensal flora 
In contrast to healthy individuals, IBD patients, have increased reactivity to bacterial components from their 
commensal flora. To address if antigen-specific responses are developed following E. coli colonization towards 
the commensal flora in absence of gross and histological lesions, humoral and cellular responses were analyzed. 
Serum collected from three week E. coli colonized animals was assessed for total IgG antibodies to altered 
Schaedler’s flora (ASF) whole cell sonicates. ELISA results indicated that no IgG antibodies were generated to 
the commensal flora (Fig 4). Although E. coli colonization did not induce antibodies reactive to the flora, CD4+ 
T cells that were harvested from MLN proliferated to antigen presenting cells that were primed with ASF 
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antigens (Fig 5).  Predominantly, CD4+ proliferation from the dual treated group was in response to ASF 
356/500/502 antigens. These results suggest that T cell proliferation to enteric flora antigens may not be a 
consequence of lesion development, but a prelude to clinical signs of IBD.  
 
Increased length of time following E. coli colonization does not increase susceptibility to 1.5% DSS  
To determine if the E. coli induced T cell reactivity to the commensal flora required more time to induce 
susceptibility to low-dose (1.5%) DSS, DF mice were colonized with the commensal strain of E. coli for 12 
weeks. After 12 weeks, separate groups of control and E. coli-colonized DF mice were administered 1.5% DSS 
in their drinking water for five days followed by four days restitution. Gross clinical signs of colitis did not 
increase with time of E. coli colonization and were similar to clinical signs at three weeks. E. coli colonization 
did not increase cecal scores or decrease colon length following administration of 1.5 % DSS and histological 
evaluation revealed similar findings (Fig 6-8).  
 
CD4+ T cell antigen-specific proliferation to commensal flora in absence of lesions  
To determine if T cell proliferation to commensal flora was only transiently induced as a consequence of E. 
coli, T cell proliferation was assessed 12 weeks post-colonization. Similar to three week post-colonization, the 
proliferative response of MLN CD4+ T cells to the ASF antigens was also increased in absence of disease (Fig 
10). At 12 weeks compared to 3 weeks, CD4+ T cells from the dual treated group proliferated in response to 
ASF antigens including ASF 457/519 and ASF 492/360/361; however, serum antibodies were not generated to 
ASF bacterial antigens indicating that insufficient ASF antigen reached or persisted within the lymph node to 
induce antibody responses (Fig 9). Similar to responses to ASF antigens, CD4+ T cell responses to E. coli 
antigen were greater at 12 weeks post-colonization compared to those at three weeks.  
 
E. coli protects against low-dose DSS induced colitis 
To assess the local cytokines secreted in response to colonization, colonic explants were collected and incubated 
for 48 hrs at 37 ºC in complete medium. Supernatants were harvested and assessed for cytokine production from 
colonic explants. Results showed that explants obtained from the dual E. coli colonized and 1.5% DSS treated 
group secreted a reduced amount of the inflammatory cytokines including IFN-γ, IL-6, and IL-17A compared to 
explants recovered from mice treated with DSS alone (Fig 11). Comparisons of MLN CD4+ cells indicated that 
E. coli colonized mice treated with DSS had greater IL-10 secreting CD4+ cells compared to DSS only treated 
DF mice in response to pooled ASF, 457/519, and E. coli antigens (Fig 12). This indicates that E. coli may 
protect against low-dose DSS-induced colitis.  
 
 
Commensal E. coli does not protect against high-dose DSS 
There are many probiotic studies reporting the beneficial attributes of E. coli in preventing/ameliorating disease. 
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For example, colonization of conventional mice with the Nissle 1917 strain has been shown to increase 
antibacterial peptides, prevent and/or improve acute colitis, and prevent chronic colitis (9, 10). Because E. coli 
decreased proinflammatory cytokines and increased IL-10 secreting CD4+ T cells, we hypothesized that these 
responses may be protective against a greater inflammatory insult. Defined flora mice were colonized with E. 
coli for three weeks prior to administration of a dose of 2.5% DSS in drinking water for six days preceding 
three days of restitution. In contrast to the results obtained with 1.5 % DSS, DF mice colonized with E. coli and 
treated with 2.5% DSS developed clinical signs of colitis including lack of formed fecal pellets, shortened 
colon, and watery mucoid contents, but also presented with severe cecal atrophy, cecal emptying and gained 
less weight than other treatment groups (Fig 13-16).  The gross lesions were consistent with the increase in 
severity of histological lesions predominantly in the ceca and characterized by the infiltration of mononuclear 
and numerous polymorphonuclear cells (Fig 13-16). Increased cecal severity may be due to the increase in 
antigenic load in the ceca.  
 
High dose DSS does not induce humoral reactivity to commensal flora 
The administration of a greater inflammatory insult and the consequence of increased severity of lesions 
prompted an examination of the humoral response to the ASF in the dual E. coli plus 2.5 % DSS group. Similar 
to the mice in the three week E. coli colonization and low-dose DSS group, the dual group did not increase their 
serum antibody responses to commensal flora members (Fig 17); however, CD4 T cell proliferation after 
stimulation with ASF antigens was comparable to that at 3 weeks post-colonization (data not shown).   
 
Local inflammatory cytokines are elevated in response to E. coli and high-dose DSS  
To determine how the local environment responded to the dual treatment group of E. coli colonization and high-
dose DSS, 3 mm diameter colonic explants were placed into complete medium and supernatants were collected 
after 48 hours. Results indicated that the dual group had elevated IL-6 and IL-17A compared to the other 
treatment groups and the dual group had elevated IFN-γ compared to the dual group with a low-dose of DSS 
(Fig 18). This indicates that commensal E. coli colonization may predispose to IBD under a high inflammatory 
trigger. IL-17A has been implicated in many autoimmune inflammatory diseases including rheumatoid arthritis, 
multiple sclerosis, asthma, and IBD (11). DF mice colonized with E. coli and treated with 2.5 % DSS increased 
MLN CD4+ antigen specific IL-17A secretion to commensal flora species. 
 
Conclusions 
The microbiota of the human gut play a pivotal role in the development of IBD. The fact that there are 
10 to100 times more bacterial cells occupying the human body compared to somatic host cells clearly 
demonstrates the necessity for a controlled relationship between the host and its microbiota in order to maintain 
GI tract harmony (1). An uncontrolled and persistently excessive T cell effector response to bacterial antigens 
has been implicated in the development of IBD (7, 12, 13). Although a single bacterial species has not been 
 66 
implicated as the specific inducer of IBD, patients with active CD have a decrease in diversity of bacterial 
species within the colon. Patients have also been reported to have an accumulation of various E. coli strains at 
inflamed tissue sites (14-16). Previous experiments indicated that colonization of defined flora mice with a 
bacterial provocateur, H. bilis, induced susceptibility to a low-grade (1.5% DSS) inflammatory trigger. 
Although H. bilis is mildly pathogenic, we questioned whether colonization of DF mice with any novel 
organism could disrupt mucosal homeostasis and induce susceptibility to a low-grade colitic insult. A 
commensal E. coli strain previously isolated from conventional flora C3H mice was confirmed to be negative 
for the following virulence factors: cvaC, iroN, ompTp, hlyF, etsA, iss, aerJ, ireA, papC, cdtA, cdtC, and cdtB 
by PCR. Defined flora mice were colonized with E. coli for three weeks and then administered a low dose 
(1.5%) of DSS. Dually treated mice did not develop clinical or histological signs of IBD; however, the 
mesenteric lymph node had CD4+ T cells that proliferated following stimulation with antigens derived from the 
eight members of the ASF. It was hypothesized that the presence of T cells reactive to the ASF antigens 
contribute to the predisposition to colitis and that a longer colonization time would manifest an increased 
sensitivity to the colitic insult. To test this hypothesis, mice were colonized for 12 weeks prior to DSS 
treatment; however, similar results were obtained.  To determine how the local environment was aiding in the 
bacterial-specific T cell proliferation, the profile of cytokine production was examined from MLN CD4+ T cells 
and colonic explant cultures. Low-dose DSS treatment alone increased IFN-γ, IL-6, IL-12/23(p40) and IL-17 in 
colonic explants relative to control DF mice, However, the MLN cells recovered from DF mice receiving the 
dual E. coli and DSS treatment presented with reduced amounts of these cytokines compared to DSS alone. 
Following E. coli colonization, CD4+ T cells recovered from the MLN secreted more IL-10 in response to the in 
vitro stimulation with bacterial antigens that did CD4+ T cells from control mice. Based on these observations, it 
was hypothesized that this strain of E. coli induced probiotic or cytoprotective mechanisms that ameliorated or 
attenuated DSS-induced colitis. Other research has shown that treatment of dendritic cells with muramyl 
dipeptide, a component of peptidoglycan degradation, upregulates NOD2 and protects against DSS- and TNBS-
induced colitis (17). To further evaluate the potential protective benefits of the commensal E. coli strain, DF 
mice were treated with 2.5 % DSS in their drinking water three weeks after colonization. In contrast to the 
results observed using 1.5 % DSS, mice that received the dual treatment displayed even greater lesion severity 
including typhlocolitis than the 2.5 % DSS treatment alone. The cecum was markedly more affected in the dual 
group as evidenced by the significant increase in the histological and macroscopic lesion scores in comparison 
to those for the colon, which may correspond to increased antigenic load in the cecum relative to the colon. 
Analysis of cytokine responses revealed enhanced secretion of IFN-γ, IL-6, and IL-17 in the high dose dually 
treated group compared to the low dose (1.5%) DSS dually treated group. In comparison to E. coli colonization 
alone and low-dose DSS treatment, the MLN CD4+ T cells from DF mice colonized with E. coli and exposed to 
the higher dose of DSS induced a greater concentration of antigen-specific IL-17 in response to in vitro 
stimulation with antigens from the commensal flora. Likewise, assessment of the local production of cytokines 
within the cecal tissue showed elevated expression of mucosal IL-17A in the dually treated group compared to 
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DSS alone. Although colonic explants form E. coli-colonized DF mice treated with the low-dose of DSS also 
demonstrated increased amounts of mucosal IL-17A compared to the other groups, the fold change was much 
greater when the mice were treated with the higher dose of DSS in conjunction with E. coli colonization. IBD 
patients have been shown to have elevated levels of IL-17A mRNA in colonic mucosa and IL-17 secreting T 
cells (11, 18). IL-17 has been reported to be important for the clearance of pathogenic bacteria such as 
Klebsiella pneumoniae, Citrobacter rodentium, and Borrelia burgdorferi (19-21). Although the E. coli strain 
used in these studies does not possess virulence attributes characteristic of invading or attaching pathogens, the 
combination of colonization along with the exposure to 2.5 % DSS may disrupt tight junctions in epithelial cells 
to increase permeability, thus allowing E. coli to “translocate” across the mucosal epithelium. IL-17 producing 
T cells may also be induced due to processing E. coli by DCs. van Beelen et al (2007) showed that NOD2 
activation stimulated human DCs to upregulate IL-1β and IL-23, resulting in production of IL-17 by memory 
Th17 cells (22). Likewise, DCs harvested from human CD patients having mutations in NOD2 that were primed 
with MDP and Pam3CSK4 and incubated with T cells were unable to induce production of IL-17 compared to 
NOD2 sufficient DCs. The development and implementation of a multi-hit model of colitis may allow for the 
incremental characterization of lesion development in  response to varying inflammatory insults. For example, 
commensal E. coli is not detrimental to our health under homeostatic conditions; however, colonization may 
facilitate enhanced sampling of the commensal flora, thus, priming the immune response to a downstream 
environmental trigger/stressor. AS IBD patients experience periods of quiescence followed by active 
inflammatory flares, this multi-hit model may allow us to elucidate the disease related mechanisms that are 
responsible for the “peaks” and “valleys” associated with active IBD. The use of commensal bacteria as 
probiotic treatments has been the focus of much attention; however, results have been contradicting and no 
probiotic “cure” has been established for IBD.  Studies using Lactobacillus or Bifidobacterium species as a 
maintenance treatment in UC have shown that treatment with lactobacilli did not change the relapse rates in 
patients; in contrast, another study found that patients that were administered bifidobacterial-derived 
supplements had fewer relapses (23, 24). Comparing relapse rates of 327 patients using no other commonly 
prescribed medications for IBD, it was observed that there was no difference in the rate of relapses when 
comparing administration of the commensal E. coli Nissle 1917 strain to an anti-inflammatory agent, 
mesalazine (25). Others have found that E. coli Nissle 1917 is just as effective as mesalazine in preventing 
relapses over 12 weeks (26). One reason for the variation in results related to the efficacy of probiotic 
treatments may be due to how the commensal organism interacts with the intestinal mucosal and how these 
interactions may or may not predispose the host for periods of increased sensitivity to inflammatory stressors. 
Variability in patient’s exposure to a potential plethora of environmental insults may greatly influence the 
efficacy of various E. coli strains as probiotics, similar to results in this study. Therefore, care should be taken 
to thoroughly evaluate the effects of probiotic bacteria on mucosal health in the context of varying 
inflammatory insults in order to develop safe and efficacious strategies to enhance gut health. 
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Figures  
 
 
 
 
 
Figure 1. 3 week E. coli colonization does not enhance DSS-induced colitis. Mice were colonized for 
three weeks prior to low dose, 1.5% DSS treatment in drinking water. Colon and ceca were harvested and 
measured for colon length (inset) and gross cecal score. A) control, B) 1.5% DSS, C) E. coli, D) E. coli + 
1.5% DSS. Gross photos demonstrate that the dual treatment group did not display more severe clinical 
signs than other treatment groups. Photographs are representative of each treatment group. n =5 to 8 mice 
per treatment group. Representative of three independent experiments.  
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Figure 2. E. coli colonization does not affect gross clinical signs of DSS-induced colitis. Defined flora 
mice were colonized with commensal E. coli for three weeks prior to administration of 1.5% DSS. Ceca and 
colon were harvested at necropsy and measured for gross clinical signs of IBD. A) colon length (cm), B) 
cecal score (0-7). The horizontal line represents the mean. n = 6 to 9 per treatment group. Representative of 
three independent experiments. There were no significant differences between treatment groups.  
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Figure 3. No histological difference between E. coli dual group and control groups. Proximal colon and 
ceca were preserved in formalin at time of necropsy, paraffin embedded and cut into 5 µm sections. Tissues 
were scored upon mucosal height, necrosis, edema, inflammation, and erosion. A) colonic score, B) cecal 
score. The horizontal line represents the mean. n = 6 to 9 mice per treatment group. Representative of three 
independent experiments. There were no significant differences between treatments. 
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Figure 4. E. coli colonization does not increase antigen-specific IgG (H&L) to commensal 
flora. Serum from three week E. coli colonized mice and/or treated with 1.5% DSS was 
assessed by ELISA for reactivity to enteric flora whole cell lysates of the resident microbiota 
(ASF 356: Clostridium spp. Cluster XIV; ASF 360: L. acidophilus; ASF 361: L. murinus; ASF 
457: M. schaedleri; ASF 492: E. plexicaudatum; ASF 500: Low-G+C-content gram-positive; 
ASF 502: Clostridium spp. Cluster XIV; ASF 519: B. distasonis), and E. coli antigen. 
Absorbance (OD) was measured spectrophotometrically (405 nm). Data is presented as a mean 
+ SEM of the optical density (OD) for each treatment group of mice. * p ≤ .05 compared to 
control and DSS only. Representative of three independent experiments. 
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Figure 5. MLN CD4+ T cells from E. coli colonized DF mice proliferate to antigens derived from 
the commensal flora. Three weeks after E. coli colonization and/or 1.5% DSS treatment, CD4+ T cells 
were recovered from mesenteric lymph node and stimulated with splenic antigen presenting cells that 
had been primed with antigens from the resident microflora (ASF 356: Clostridium spp. Cluster XIV; 
ASF 360: L. acidophilus; ASF 361: L. murinus; ASF 457: M. schaedleri; ASF 492: E. plexicaudatum; 
ASF 500: Low-G+C-content gram-positive; ASF 502: Clostridium spp. Cluster XIV; ASF 519: B. 
distasonis, or pooled ASF WCS). T cells and APCs were mixed at a ratio of 1:1 and incubated for 72 
hours. Proliferation was assessed via 3H-thymidine incorporation. Data is represented by mean + SEM 
of counts per minute. n = two per treatment group. Representative of two independent experiments.   
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Figure 6. 12 week E. coli colonization does not enhance susceptibility to 1.5% DSS. 
Following 12 weeks of E. coli colonization and/or low-dose, 1.5% DSS, proximal colon 
and ceca were harvested at euthanasia and scored based upon gross and histological 
evaluations. Colon length and gross cecal appearance (left) and hematoxylin and eosin 
stained sections of colon (right). A, D)-controls, B, E) 1.5% DSS, C, G) E. coli colonized, 
D, H) E. coli and 1.5% DSS treated.  Photos were representative of mean treatment scores. 
n = 7 to 9 per treatment group. Representative of two experiments.  
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Figure 7. 12 week E. coli colonized and1.5% DSS treated dual group does not induce macroscopic 
signs of IBD. Defined flora mice were colonized with commensal E. coli for 12 weeks and/or 
administrated 1.5% DSS in drinking water. Ceca were blindly scored as 0=healthy to 7=disease (A) and 
colon length was measured (B) for gross clinical signs of IBD. Data is represented by mean + SEM. n = 7 
to 9 mice per treatment group. There were no significant differences between treatments. Results are 
representative of two experiments. 
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Figure 8. No histological evidence of lesions in dual E. coli colonized and low-dose DSS treated mice. 
Following 12 weeks of E. coli colonization, and/or 1.5% DSS treatment, proximal colon and cecal sections 
were scored were based upon crypt and villus height, necrosis, inflammation, erosion, ulceration, mucosal 
hyperplasia and edema. 0=healthy and 35=diseased A) colon score, B) cecal score. Data is represented by 
mean + SEM. n = 7 to 9 mice per treatment group. There were no significant differences between 
treatments. Results are representative of two experiments. 
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Figure 9. E. coli colonization and DSS treatment does not induce 
antibody response to resident flora. Serum from 12 week E. coli 
colonized mice and/or treated with 1.5% DSS was assessed by ELISA for 
total IgG reactivity to enteric flora whole cell lysates of the resident 
microbiota (ASF 356: Clostridium spp. Cluster XIV; ASF 360: 
Lactobacillus acidophilus; ASF 361: L. murinus; ASF 457: M. schaedleri; 
ASF 492: E. plexicaudatum; ASF 500: Low-G+C-content gram-positive; 
ASF 502: Clostridium spp. Cluster XIV; ASF 519: B. distasonis), E. coli 
antigen or non-specific Staphylococcus epidermidis antigen. Absorbance 
(OD) was measured spectrophotometrically (405 nm). Data is represented 
by mean + SEM of the optical density (OD). n = 10 to15 mice per 
treatment group. Results are representative of two experiments for each 
treatment group of mice. Significance is indicated p < .05*. 
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Figure 10. E. coli and DSS treatment increased antigen specific CD4+ T cell 
proliferation. Following 12 weeks of E. coli colonization and/or 1.5% DSS treatment, 
mesenteric lymph node T cells were enriched from mice colonized with H. bilis for 12 
weeks and stimulated with splenic antigen presenting cells (primed with resident microflora: 
ASF 356: Clostridium spp. Cluster XIV; ASF 360: L. acidophilus; ASF 361: L. murinus; 
ASF 457: M. schaedleri; ASF 492: E. plexicaudatum; ASF 500: Low-G+C-content gram-
positive; ASF 502: Clostridium spp. Cluster XIV; ASF 519: B. distasonis) at 1:1 ratio for 72 
hours. Proliferation was assessed via 3H-thymidine incorporation. Data is represented by 
mean + SEM. n = one to three pooled CD4+ T cells per treatment group. Significance within 
stimulation groups is indicated by different letters. Results are representative of two 
experiments for each treatment group of mice. 
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Figure 11. Mucosal inflammatory cytokines are decreased in E. coli and 1.5% DSS dual treatment 
group. Ex vivo colon cultures (assessed by LUMINEX technology) of A) IFN-γ, B) IL-12/23, C) IL-6 
(p40), and D) IL-17A protein analysis from defined flora mice colonized with E. coli for 12 weeks and/or 
treated with 1.5% DSS. Data is represented by mean + SEM. n = 7 to 9 mice per treatment group. Results 
are representative of two experiments for each treatment group of mice. For each treatment group, 
statistical significance is indicated by different letters. 
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Figure 12. E. coli colonization increased IL-10 production in mesenteric lymph node. 
Mesenteric lymph node CD4+ T cell secretion of IL-10 following stimulation with splenic 
antigen presenting cells (primed with resident microflora: ASF 356: Clostridium spp. Cluster 
XIV; ASF 360: L. acidophilus; ASF 361: L. murinus; ASF 457: M. schaedleri; ASF 492: E. 
plexicaudatum; ASF 500: Low-G+C-content gram-positive; ASF 502: Clostridium spp. Cluster 
XIV; ASF 519: B. distasonis or pool of all 8 ASF) at 1:1 ratio (T cell: APC) for 72 hours from 12 
week E. coli colonized defined flora mice compared to non-colonized. Data is represented by 
mean + SEM. n = one to three pooled CD4+ T cells from each treatment group. Representative of 
two experiments. 
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Figure 13. E. coli and high dose DSS treatments 
induce greater severity of disease. Defined flora mice 
were colonized with E. coli for three weeks and/or 
treated with 2.5% DSS in drinking water. Gross scores 
including cecal score and colon length were measured. 
Gross photos demonstrate that the dual treatment group 
had decreased cecal/colonic contents, thicked and 
shorted colon length (numbers on upper right corner), 
cecal atrophy, and blunting. Photos representative of 
each treatment group. A) Control, B) 2.5% DSS treated, 
C) E. coli colonized, D) E. coli colonized and 2.5% DSS 
treated. n = 5 to 10 mice per treatment group. 
Representative of two independent experiments.  
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Figure 14. E. coli colonization and high dose DSS induce 
typhlocolitis. Defined flora mice were colonized with E. coli for 
three weeks and/or administered 2.5 % DSS. Weight gain/loss 
was evaluated (A), Ceca were blindly scored as 0=healthy to 
7=disease (B) and colon length was measured (C). Data is 
represented by mean + SEM. n = 5 to 12 mice per treatment 
group. Representative of two independent experiments. Statistical 
significance is indicated by different letters.  
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Figure 15. E. coli colonization and high dose (2.5%) DSS induced greater lesion 
severity in cecum. Photomicrographs of proximal colon (right) and ceca sections (left) 
following three weeks of E. coli colonization and/or 2.5% DSS stained with 
hematoxylin and eosin. A, E) control, B, F) DSS, C, G) E. coli, D, H) E. coli + 2.5% 
DSS. Photomicrographs representative of mean treatment scores from each group, 
depicting enhanced severity of cecal tissue characterized by gland dropout, 
inflammatory mono/polynuclear infiltrate and mucosal hyperplasia in (D). n = 5 to 12 
per treatment group. Representative of two experiments 
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Figure 16. E. coli & High Dose DSS Enhance Histological Cecal Score. Histological scores following 3 
weeks of E. coli colonization, and/or 2.5% DSS treatment, proximal colon (B) and cecal sections (A) were 
scored were based upon crypt and villus height, necrosis, inflammation, erosion, ulceration, mucosal 
hyperplasia and edema. 0=healthy and 35=diseased Data is represented by mean + SEM. Statistical 
significance is indicated by different letters. n = 5 to 12 per treatment group. Scores are representative of two 
independent experiments.  
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Fig 17.  E. coli colonization and high dose DSS do not elevate serum antibodies to 
commensal flora members. Serum from three week E. coli colonized mice and/or 
treated with 2.5% DSS was assessed by ELISA for total IgG reactivity to enteric flora 
whole cell lysates of the resident microbiota (ASF 356: Clostridium spp. Cluster XIV; 
ASF 360: L. acidophilus; ASF 361: L. murinus; ASF 457: M. schaedleri; ASF 492: E. 
plexicaudatum; ASF 500: Low-G+C-content Gram-positive; ASF 502: Clostridium spp. 
Cluster XIV; ASF 519: B. distasonis), E. coli antigen or non-specific Helicobacter 
hepaticus antigen. Absorbance (OD) was measured spectrophotometrically (405 nm). 
Data is represented by mean + SEM of the optical density (OD) for each treatment 
group of mice. Statistical significance indicated is p < .05*. n = 5 to 10 mice per 
treatment group. Results representative of two independent experiments. 
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Figure 18. E. coli and high DSS dual group induces elevated inflammatory cytokines locally. Ex vivo 
colon cultures (assessed by LUMINEX technology of A) IFN-γ, B) IL-17A, C) IL-6 (p40), D) IL-12/23(p40)  
protein analysis from defined flora mice colonized with E. coli and/or treated with 2.5% DSS. Data is 
represented by mean + SEM. n = 5 to 10 mice per group. Statistical significance indicated by different letters. 
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Figure 19. Greater Inflammatory Dose positively correlates with antigen specific IL-17 expression to 
resident flora. (A, B) Mesenteric lymph node CD4+ T cell secretion of IL-17A following stimulation with splenic 
antigen presenting cells (primed with resident microflora: ASF 356: Clostridium spp. Cluster XIV; ASF 360: L. 
acidophilus; ASF 361: L. murinus; ASF 457: M. schaedleri; ASF 492: E. plexicaudatum; ASF 500: Low-G+C-
content gram-positive; ASF 502: Clostridium spp. Cluster XIV; ASF 519: B. distasonis) at 1:1 ratio for 72 hours 
from 3 week E. coli colonized and 2.5% DSS (A) or 1.5% DSS (B) compared to non-colonized. Data is represented 
by mean + SEM (C, D) Mucosal IL-17A expression is elevated in cecum following 3 week E. coli colonization and 
2.5% DSS (C) or 1.5% DSS (D). Data is represented as fold change compared to GAPDH. n = 2 to 12 per 
treatment group. Statistical significance is indicated by different letters. 
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CHAPTER 4. Predisposition to Colitis: Differential Responses of Intestinal 
Epithelial cells Following Exposure to Helicobacter bilis in Comparison to 
Escherichia coli 
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Abstract 
While the etiology of inflammatory bowel disease (IBD) is unknown, genetics, microflora, mucosal 
permeability, and aberrant immune responses have been implicated. The interactions between luminal bacteria 
and host epithelial cells that contribute to the development of IBD are not well characterized. In the absence of 
mucosal inflammation, colonization of the intestinal epithelium with bacterial provocateurs may increase host 
sensitivity to colitis. Our laboratory has previously shown that defined flora mice colonized with Helicobacter 
bilis, unlike a commensal Escherichia coli, developed antibody responses to the resident flora and became 
susceptible to colitis induced by a low dose of dextran sulphate sodium (DSS). Interestingly, both the 
pathogenic H. bilis, and the commensal E. coli, induced antigen-specific CD4+ T cell responses to the 
commensal microbiota. By using a greater inflammatory stressor (2.5% DSS), E. coli colonized mice were 
predisposed to a severe typhlocolitis or cecitis. The interaction between luminal bacteria and host epithelial cells 
are likely central to the induction of colitis. We hypothesized that changes in host-susceptibility to colitis 
induced following colonization with a bacterial provocateur is compartmentalized to the epithelium. The present 
studies were designed to define responses of an intestinal epithelial cell line (MODE-K) colonized with either 
H. bilis or E. coli that would elucidate the differential ability of these organisms to effect changes in mucosal 
homeostasis and predispose defined flora mice to the onset of colitis. A murine epithelial cell line, MODE-K, 
was exposed to viable H. bilis or E. coli or whole cell sonicates (WCS) for 12 to 48 hours. Cells and 
supernatants were collected and evaluated for cytokine secretion and chemokine RNA expression. Cell viability 
following addition of the bacteria to cell culture was measured by an MTT assay and indicated that both H. bilis 
and E. coli were cytotoxic for MODE K cells following 12 hours of cell culture (p < .05). After as little as 12 
hours, MODE K cells exposed to E. coli expressed elevated levels of the proinflammatory cytokine, IL-6 
compared to that induced by H. bilis. However, H. bilis increased expression of CXCL9 and MIP-2. E. coli 
incubation of MODE-K cells for 24 hours resulted in similar secretion of chemokines as H. bilis colonization 
including MCP-1 and RANTES. However, live bacteria were not required to induce these chemokines as WCS 
also increased production of these cytokines. Collectively, these data indicate that although H. bilis and E. coli 
differ in virulence attributes, the direct effects of their interactions with epithelial cells are minimal indicating 
that predisposition to an inflammatory insult may depend upon other innate/adaptive cell populations resident to 
or infiltrating the mucosa. Results suggest that bacterial colonization of the mucosal epithelium provokes innate 
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responses that contribute to the induction of mucosal inflammation. These studies are correlate with in vivo 
observations (chapter #3) demonstrating that the nature of the bacterial provocateur is a critical factor affecting 
the predisposition of the host to a colitic insult 
 
Introduction 
Inflammatory Bowel Disease (IBD) is a chronic inflammation of the gastrointestinal tract and that 
results in patients suffering with abdominal pain, nausea, diarrhea and vomiting. Although genetics, a breach in 
epithelial permeability, and aberrant immunity to members of the resident microbiota have been implicated in 
the etiology of IBD, it is widely accepted that an inappropriate response to the commensal flora drives the 
pathogenesis. For example, rodent models of IBD including IL-2-/-, IL-10-/-, T cell receptor alpha deficient mice 
and HLA-B27 rats maintained in germ-free conditions do not develop IBD; however, colonization with 
commensal bacteria results in the development of colitis in these mice and rats (1-4). Furthermore, human IBD 
patients develop serological responses to bacterial components including antibodies to the outer membrane 
porin C (OmpC) of Escherichia coli (5, 6). Previous studies from this laboratory have demonstrated that 
colonization of defined flora mice with a novel organism predisposed defined flora mice to DSS-induced colitis. 
The nature of the provocateur (e.g., virulence attributes) may determine the degree of susceptibility; however, 
both a pathogenic and commensal bacteria were shown to be able to induce antigen-specific CD4+ T cell 
reactivity to the commensal flora indicating and supporting evidence of the complex nature of the responses 
associated with the induction and/or maintenance of IBD.  
To determine if Helicobacter bilis or E. coli preferentially exacerbate the susceptibility to DSS-
induced colitis is due to the initial bacteria-epithelial cell interactions, an intestinal cell line was utilized to 
analyze chemokine and cytokine expression following exposure of MODE K cells to these two bacterial 
species.  Results indicated that H. bilis and E. coli have different effects on MODE-K epithelial cells. The 
differential modulation of epithelial genes and proteins following treatment with a pathogen or commensal 
indicate initial responses may be critical to the development of host responses to chronic provocateurs. 
 
 
Materials & Methods 
 
Cell Culture 
MODE-K cells are a polarized duodenal epithelial cell line from C3H/HeJ mice, immortalized with SV40 (7). 
Cells were and maintained in DMEM (high glucose-Cellgro) supplemented with 10% FBS, 
penicillin/streptomycin, 25 µg/ml gentomycin, L-glutamine, non-essential amino acids, 1 mM Na-pyruvate, and 
2 mg/ml insulin. Cells were plated in a 24-well flat bottom plates (Costar 3512) at 8 x 104 cells per well and 
incubated at 37ºC in 5% CO2. After 12-20 hours, when cells developed a flat and adherent morphology and 
were approximately 70-80% confluent, bacteria were added at a 1:200 ratio of cells: bacteria (8 x 106cells/well). 
Bacteria were enumerated using a Petroff-Hausser chamber. Whole cell sonicates (WCS) were added at 59 
µg/ml of protein, which was equivalent to a 1:200 dilution by BCA assay. Cultures were incubated at 37ºC in 
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5% CO2 for 12-24 hours and 100 µl of supernatant was collected and replaced with fresh media at each time 
point. After 12 hours of cell culture, supernatants were completely extracted off of MODE-K cells and cells 
were dissociated from plates by adding .5 ml of non-enzymatic cell dissociation solution (1X) (Sigma) to each 
well. Plates were incubated at 37ºC in 5% CO2  for 10 minutes and then firmly tapped against bench top to 
dissociate cells. Cells were washed in media and resuspended in RNALater for RNA extraction. 
 
Bacterial Preparation 
H. bilis was cultivated on modified Columbia broth agar plates containing , Isovitalex (BD), yeast extract (BD), 
casamino acids (Difco) and 10% bovine blood. 1-2 mls of sterile brucella broth containing 20% newborn calf 
serum was overlayed on each plate. Plates were under microaerophilic conditions using a gas mixture 
containing 90 % N2, 5% CO2 and 5% H2 and incubated at 37ºC for 12-24 hours. Microscopic evaluation of H. 
bilis was performed by  wet mount to assess viability based upon degree of  darting motility. Blood agar plates 
were inoculated with H. bilis and incubated aerobically prior to experimental assays to check for contamination. 
E. coli was cultivated on blood agar plates and inoculated into Brucella broth for 5-8 hours. H. bilis and E. coli 
were counted using a Petroff-Hauser chamber and prepared at 8 x 106 bacteria/ml. One ml of bacteria (8 x 106 ) 
was added to each well containing MODE-K cells. Whole cell sonicates were prepared as previously described 
(8). Briefly, WCS was sterilized by UV light irradiation and stored at –20 °C until use. Sterility of each 
individual WCS was confirmed by culturing on blood agar plates overnight. WCS were added at 59 µg/ml 
(protein concentration equivalent to 1:200 cells: live bacteria by BCA assay). 
 
Analysis of Cell Cytotoxicity  
Cell viability was measured by the ability of mitochondrial dehydrogenases to cleave the tetrazolium ring of 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) (Sigma). Cleavage of the tetrazolium ring 
results in the formation of insoluble formazan crystals that were dissolved by acidified isopropanol. The 
resultant color change (purple solution) was measured by a spectrophotometer at 570 nm following subtraction 
of the background absorbance measured at 690 nm.   
 
Chemokine and Cytokine Analysis Utilizing Real Time Quantitative PCR 
Total RNA was extracted from MODE-K cells using the RNAeasy Mini Kit (Qiagen) as described by the 
manufacturer. The RNA samples were quantified by ND-1000 spectrophotometer (Nanodrop technologies) and 
treated with TURBO DNA-free DNase at 2U/µl (Ambion) to eliminate genomic DNA contamination. 5 µg of 
RNA was reverse transcribed into cDNA by SuperScript™ III First-Strand Synthesis System (Invitrogen, San 
Diego, CA). cDNA was amplified using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen). The 
following PCR conditions were used: 95°C for 10 minutes followed by 40 cycles of amplification (95°C for 10 
seconds, 56°C for 5 seconds, and 72°C for 10 seconds). Primers for glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) (forward primer: 5’- TCACCACCATGGAGAAGGC-3’, reverse primer: 5’-
GCTAAGCAGTTGGTGGTGCA-3’) MIP-2 (forward primer: 5’-GAGTAACCCTTGGACATTTT-3’, reverse 
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primer: 5’-ACGAAAGGCATGACAAAAC-3’), CXCL9 (forward: 5’-TTTTCCTTTTGGGCATCATC-3’, 
reverse primer: 5’-AGCATCGTGCATTCCTTATC-3’) and IL-6 (forward primer: 5’-
CTGAGAGCTGCCCCTTCACT-3’, reverse primer: 5'-CCACACCCACCAGCATCTTC-3’) were used. The 
qRT-PCR was performed using Applied Biosystems GeneAmp™ 5700 Sequence Detection System.  Standard 
curves for each gene were made using a series of cDNA dilutions. The relative RNA quantity of each gene was 
normalized to GAPDH (9). 
 
Chemokine Analysis Using LUMINEX Technology 
Following 12-24 hours of MODE-K incubation with bacteria or WCS, 100 µl of cell supernatants were 
collected for cytokine analysis by the Luminex 100 technology. A mouse chemokine kit was purchased 
(Millipore) to evaluate GM-CSF, MCP-1 and RANTES proteins.   
 
Statistical Analysis 
Data is displayed as mean + SEM. Non-parametric group comparisons were analyzed by Kruskal-Wallis tests. 
Parametric group comparisons were analyzed by analysis of variance (ANOVA). Pairwise group comparisons 
having equal variances were analyzed using t-tests. 
 
Results & Discussion 
 
Commensal E. coli and H. bilis induce cell cytotoxicity 
In vivo experiments from defined flora mice colonized with E. coli or H. bilis indicated that both organisms 
increased the susceptibility of DF mice to DSS-induced colitis, a lesser dose of DSS (1.5 %) was required to 
induce inflammation in H. bilis colonized DF mice compared to the 2.5 % dose of DSS used to induce colitis in 
E. coli colonized DF mice. To determine if H. bilis exposure was differentially affecting the health of the 
colonic epithelium, a viability assay was performed following bacterial treatment of MODE-K cells following 
12-48 hours of incubation with live H. bilis or E. coli. Results indicated that H. bilis colonization significantly 
(p < .05) increased cell cytotoxicity following 12, 24, or 48 hours compared to cells incubated with medium 
alone or E. coli treated cells (Fig 1). Exposure of MODE-K cells to E. coli also decreased cell viability 
indicating that both bacteria negatively affect mitochondrial health. 
 
Viable bacteria not required for secretion of MCP-1 and RANTES 
The acute phase of IBD is characterized by the infiltration of neutrophils into the lamina propria of the colon or 
small intestine, whereas the chronic stages include the infiltration of neutrophils, T cells, macrophages, mast 
cells and eosinophils (10). The recruitment of cells to effector sites involves activation of the endothelium, 
rolling, tethering, and migration to sites of inflammation. Dysregulation in any of these processes may 
contribute to IBD development. IBD patients have elevated expression of CC chemokines in inflamed tissues 
and human colonic epithelial cell lines have been reported to secrete and express IL-8, MCP-1 and GM-CSF in 
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response to bacterial invasion (11-13). To determine if H. bilis recruits monocytes early in colonization, 
contributing to its virulence, CC chemokines including monocyte chemotactic protein-1 (MCP-1), and regulated 
upon activation, normal T-cell expressed and secreted (RANTES) were assessed from supernatants collected 
from MODE K cells following bacterial colonization for 12-24 hours. Granulocyte-macrophage colony-
stimulating factor (GM-CSF) was also assessed. The addition of live H. bilis to MODE-K cells decreased 
production of MCP-1 and RANTES compared to cells only, however, H. bilis whole cell sonicates (WCS) 
increased their production indicating that MCP-1 and RANTES production does not require the presence of 
viable bacteria (Fig 2). H. bilis increased GM-CSF levels above WCS stimulation or E. coli stimulation. 
Interestingly, levels of MCP-1 and RANTES were similar between H. bilis and E. coli treated cells indicating 
that an additional cell type may be required to induce susceptibility. E. coli WCS also increased the levels of 
MCP-1 and RANTES above concentrations with live E. coli suggesting that toll-like receptor activation may 
drive the initial recruitment of monocytes and granulocytes.  
 
Commensal E. coli increased epithelial IL-6 expression 
IL-6 is a potent, multifunctional cytokine that plays an important role in acute inflammation and IBD patients 
have elevated levels of IL-6 in their serum (14). To determine if MODE-K cells expressed IL-6 following 
treatment with H. bilis or E. coli, cells were assessed for IL-6 expression by quantitative RT-PCR. Results 
indicated that E. coli increased IL-6 expression in MODE-K cells compared to H. bilis treated cells or WCS.  
 
H. bilis evoked MIP-2 and CXCL9 Synthesis 
The human CXC chemokine, IL-8 is a potent neutrophil attractant secreted in response to bacterial stimulation 
and products (15, 16). IL-8 has been implicated in the pathogenesis of IBD due to elevated levels of protein 
observed in active inflammatory tissues of IBD patients (17). The murine homologue of IL-8 is MIP-2 (18) and 
quantitative RT-PCR results indicated the H. bilis exposed MODE-K cells expressed significantly (p < .05) 
elevated MIP-2 and CXCL9 RNA compared to E. coli treated or WCS (Fig 4). CXCL9 (monokine induced by 
IFN-γ (MIG)) is expressed on the surface of epithelial cells, amongst others and is a chemoattractant for 
neutrophils, T and B cells (19-21).  
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Conclusions 
The gastrointestinal tract contains a single layer of epithelial cells that serves to provide a physical, 
mechanical, and chemical barrier between the host and the luminal contents. These cells make the distinction 
between food antigens, pathogens, and commensal organisms on a daily basis. It is also quite clear that there is 
cross-talk between the mucosal epithelium and the intestinal microbiota (22-24). Previous experiments 
indicated that a pathogen, H. bilis and a commensal, E. coli differentially induced susceptibility to DSS-induced 
colitis following colonization of defined flora mice. We hypothesized that this increase in host susceptibility 
was likely initiated by interactions between the colonizing microorganism and the epithelium, which constituted 
the initial bacterial provocation. To test this hypothesis, an intestinal cell line, MODE-K was exposed to H. 
bilis, E. coli, or WCS. Initial experiments indicated that in vitro exposure of MODE-K cells to H. bilis 
significantly (P ≤ 0.05) decreased cell viability compared to controls. Interestingly, E. coli treated cells also 
reduced cell viability compared to control cells. Other research groups have reported that colonization of a 
human commensal E. coli on a colonic cell line increased ultrastructural changes in mitochondria morphology 
of the epithelium, increased permeability of epithelial barrier, and mediated cytoskeletal and tight junction 
protein rearrangements (25). The metabolic stress/cytotoxicity induced by E. coli or H. bilis on the epithelium 
may enhance internalization of commensal bacteria (26) explaining why antigen-specific T cells were generated 
to the commensal flora in vivo following E. coli colonization even in the absence of detectable inflammation 
(chapter #3).  
Chemokines mediate recruitment of inflammatory cells to mucosal tissues in active IBD, however, 
they are a double edged sword in host defense in as much that they are critical for the recruitment of innate cells 
to sites of inflammation to prevent spread of invading pathogens. In contrast, the excessive infiltration of 
granulocytes, monocytes and macrophages has a negative impact on epithelial and tissue health, thus, 
contributing to the pathogenesis of IBD (27). CCL5/RANTES, and CCL2/MCP-1 are CC chemokines that can 
recruit monocytes and promote transepithelial migration of TCRαβ+ and TCRγδ+ T cells (28). CC chemokines 
including RANTES and MCP-1 have been reported to be elevated and correlate with increased leukocyte 
infiltration in colonic tissue during active colitis (29-32). Supernatants from MODE-K cells treated with WCS 
of H. bilis or E. coli contained elevated MCP-1 and RANTES proteins compared to treatment with live H. bilis 
or E. coli. MCP-1 has also been reported to promote Th2 immunity as evidenced by the fact that MCP-1 
deficient mice are incapable of generating Th2 responses (33). Previous in vivo experiments with H. bilis and E. 
coli colonization of defined flora mice demonstrated an elevated Th1/Th17 phenotype indicated by IgG2a 
antigen-specific antibodies and cytokine secretion by CD4+ mesenteric lymph node cells (chapter #3). 
Therefore, speculative evidence suggests that the lack of a balanced Th2 immune response following 
colonization with H. bilis and E. coli in vivo may correlate with the initial decrease of MCP-1 levels in the 
epithelium in vitro.  
IL-6 is a critical cytokine in acute inflammation and has multiple functions in innate and adaptive 
immunity. IL-6 has also been shown to activate NF-kB activity in epithelial cells, which leads to increased 
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expression of adhesion molecules (34) and promotes T cell growth and B and T cell differentiation. MODE-K 
cells were assessed for expression of IL-6 following treatment with H. bilis or E. coli live organisms or WCS. 
Results indicated that both H. bilis and E. coli live bacteria elevated epithelial IL-6 expression significantly (p < 
.05) compared to control cells or WCS. Therefore, the initial IL-6 response of the epithelium to a commensal E. 
coli or pathogenic H. bilis treatment is indifferent. It has been reported that the combination of IL-6 and TGF-β, 
can induce the Th17 cell lineage (35). Previous experiments (Chapters 2 & 3) indicated that E. coli and H. bilis 
induced mucosal IL-17 responses in vivo including antigen-specific induction of IL-17A by CD4+ T cells 
recovered from the draining mesenteric lymph node and recovery of mRNA from the proximal colon and cecal 
tissues. Therefore, acute expression of IL-6 in the epithelium may predispose to chronic in vivo IL-17 
production. IL-17A has been shown to increase chemokine expression and neutrophil recruitment in the lung 
and blocking IL-17A prevented Th17 cell-induced neutrophilia (36). To determine if H. bilis or E. coli affected 
the ability of epithelial cells to recruit neutrophils, we measured the induction of the murine homologue of 
human IL-8, MIP-2. IL-8/MIP-2 is secreted in vitro in response to bacterial stimulation and in vivo has also 
been detected in crypt abscesses and at the base of intestinal ulcers (17). H. bilis treated MODE-K cells 
expressed significantly elevated (p < .05) MIP-2 compared to E. coli or WCS treated cells. The differential 
upregulation of MIP-2 by H. bilis suggests that it is recognized as a threat by the epithelium compared to E. 
coli, which may trigger downstream adaptive immunity. A recent report indicated that a nonpathogenic E. coli 
was described to decrease TNF-α induced IL-8 expression from an epithelial cell line (37). Furthermore, 
polymorphisms in CXCL9 are associated with Crohn’s disease in children (38) and adults (39). H. bilis 
significantly (p < .05) increased CXCL9 expression compared to E. coli or WCS treated MODE-K cells 
indicating that in vivo, the host may be responding by activating neutrophils as well as lymphocytes to the site 
of colonization.  
 It has been demonstrated that epithelia exposed to live H. bilis or E. coli bacteria display reduced cell 
viability. As previously shown (26), the metabolic stress associated with the presence of these bacteria may 
induce increased uptake of commensal organisms, which may indicate why E. coli induces antigen-specific 
CD4+ T cell reactivity to the commensal flora (i.e., increased antigen uptake and processing). The epithelium 
may perceive H. bilis as threatening and induce increased chemokines synthesis including MIP-2, CLCL9, and 
GM-CSF. The cross-talk between E. coli and the epithelial cells induced IL-6 expression suggesting that 
laminal proprial lymphocytes may be activated or predisposed to a IL-17 maturation pathway. The differential 
modulation of epithelial genes and proteins following treatment of MODE K cells with a pathogen or 
commensal indicated that the acute responses may be critical to the development of host responses to the 
persistent colonization of the GI tract with bacterial provocateurs. 
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Figure 1. Epithelial exposure to H. bilis and E. coli induces cytotoxicity. MODE-K cells 
were incubated with medium alone, live H. bilis or live E. coli for 12 to 48 hours prior to 
assessment of cell viability by the MTT assay. Data is represented by mean + SEM. 
Statistical significance within treatment groups is indicated by different letters. n = three to 
nine per treatment group. Representative of two independent experiments.  
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Figure 2. Viable bacteria not required to increase secretion of MCP-1 and RANTES. MODE-K cells 
were incubated with H. bilis, E. coli or whole cell sonicates for 24 hours. Supernatants were collected and 
assessed for secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) (A-B), monocyte 
chemotactic protein-1 (MCP-1) (C-D), and regulated upon activation, normal T-cell expressed and secreted 
(RANTES) (E-F). Data is represented by mean + SEM and n= three to nine per treatment. Groups 
identified by different letters are statistically different from one another. Data representative of two 
independent experiments. 
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Figure 3. Commensal E. coli increased IL-6 expression. 
Quantitative RT-PCR analysis of IL-6 expression following 
exposure of MODE-K cells to live bacteria (1:200) or whole 
cell sonicates (WCS) for 12 hours. Data are expressed as fold 
change compared to GAPDH. Treatment groups identified 
with different letters are statistically different. n = three to 
nine per treatment group. Data representative of two 
independent experiments. 
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Figure 4. H. bilis induces expression of MIP-2 and CXCL9 mRNA. Quantitative RT-PCR was 
performed using RNA samples isolated from MODE-K cells that had been incubated with live H. bilis, E. 
coli or whole cell sonicates (WCS) of each organism for 12 hours showing elevated MIP-2 (A) and CXCL9 
(B). Data are expressed as fold change compared to GAPDH. Data is represented as the mean + SEM and n 
= 8 per treatment group. Treatment groups identified with different letters are statistically different. n = 
three to nine per treatment group. Data representative of two independent experiments. 
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CHAPTER 5. Discussion 
  
Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract primarily 
comprised of Crohn’s disease (CD) and ulcerative colitis (UC). Although the etiology of IBD has not been 
completely established, genetics, aberrant immunity, and the environment have been implicated (1). 
However, it is believed that the influence of these factors on the development of IBD is contingent upon the 
presence of a resident microbiota and that an inappropriate immune response develops in reaction to 
microbial antigens due to persistent infection, dysbiosis, and/or genetic defects that affect microbial 
clearance and epithelial barrier function (2, 3). Although the importance of the resident flora has been 
studied in multiple animal models of IBD, the complications of genetic knockouts obscure the conclusions 
(4-9). For example, the 50% of IL-2 -/- mice that do not die by 4-9 weeks after birth develop highly 
activated B and T cells and elevated antibodies in addition to pancolitis. However, if reared in germfree 
housing conditions, intestinal inflammation is delayed, but not absent (10). Because IL-2-/- mice lack 
regulatory T cells, the development of IBD is an expected outcome. The multi-factoral nature of the 
pathogenesis of IBD is driven by the hypothesis that defects in one or more aspects of the immune response 
contributes to disease (11). For example, a defect in innate immunity, toll-like receptors (TLRs), results in 
priming of CD4+ T cells resulting in disease (12). A deficiency in T regulatory cells or an excessive amount 
of effector T cells also results in IBD (13-20). Therefore, it has been hypothesized that ‘multiple hits’ or 
defects in the innate, adaptive, or regulatory immune responses are required to induce susceptibility to IBD 
in immune competent individuals (11). To be able to address how the resident flora contributes to an 
aberrant immune response in the development of IBD, one of the specific aims for this work was to develop 
a multiple-hit model of IBD in immune competent mice in order to characterize the resultant antigen-
specific immune responses following the onset of colitis. To develop a multiple-hit model of colitis in 
immune competent, defined flora mice, we introduced Helicobacter bilis as a novel, bacterial provocateur 
into the stable microbiota of defined flora mice. Human IBD patients have been shown to develop immune 
responses to Helicobacter species other than H. pylori (21). In addition, H. bilis has also been associated 
with IBD-like lesions in immunocompromised mice (22-24). For example, SCID mice colonized with H. 
bilis developed clinical signs of typhlitis by 12 weeks post-infection (22). Previous experiments from this 
laboratory indicated that H. bilis colonization of immune competent, defined flora (DF) C3H mice, induced 
immune reactivity to the resident commensal flora (25) and microarray data indicated that H. bilis 
significantly upregulated genes associated with proteolysis, glycoprotein synthesis, protein metabolism and 
immune response and significantly downregulated fatty acid metabolism, lipid metabolism and carboxylic 
acid metabolism genes (Zhiping Liu-submitted for publication).  
IBD patients typically have relapses in inflammatory episodes or flares between periods of 
quiescence. These active inflammatory episodes tend to correspond to stressful life events (26, 27). Stress 
has been shown to enhance colitis in rats and may predispose a person to IBD as well (28, 29). To induce 
environmental stress on the gut, we employed a low dose of dextran sulphate sodium (DSS) as the colitic 
insult or trigger to induce colitis. DSS has been commonly used to induce acute or chronic colitis in mice as 
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the resultant clinical signs are similar to human colitis (diarrhea, weight loss, bloody stool) (30-35). We 
hypothesized that the introduction of a novel bacterial provocateur into the established intestinal flora 
would perturb host mucosal homeostasis, inducing aberrant immune responses to the resident flora (hit #1-
H. bilis), resulting in increased vulnerability to an environmental/inflammatory insult/ stressor (hit #2-
dextran sulphate sodium (DSS) (Fig 1). Results indicated that, in comparison to DSS or H. bilis 
colonization alone, mice dually treated with H. bilis and DSS developed significantly (p < .05) increased 
clinical signs of disease including gross lesion scores, histological scores, and decreased colon length. 
Serum IgG2a responses to antigens derived from the enteric flora were increased compared to controls. 
Evaluation of tissue recovered from the proximal colon indicated an increase in mucosal IL-17, IFN-γ, and 
TNF-α after colonization and/or DSS treatment compared to other treatment groups. The magnitude of 
antigen-specific T cell proliferation increased with time, as Foxp3 expression declined; however, lesions 
did not increase in severity. Susceptibility to DSS-induced colitis correlated with the increased antigen-
specific reactivity to the enteric flora and mucosal expression of inflammatory cytokines. In conclusion, 
these studies demonstrate that perturbation of the microbial ecology following colonization with a 
pathogenic bacteria may lead to abnormal Th1 and Th17 immunity, thus, predisposing the host to an 
inflammatory insult. 
The innate and adaptive immune components of the gastrointestinal tract must maintain a 
multitude of complex functions including the differentiation between food, pathogenic, and commensal 
antigens on a daily basis. Complex mechanisms of tolerance are established to maintain homeostatic 
unresponsiveness to members of the microbiome including bacterial specific regulatory T cells, 
antimicrobial peptides, immunoglobulin A, and mechanisms of negative and positive selection in the 
thymus (20, 36). Disruption of these mechanisms may result in the generation of antigen-specific effector 
responses generated to members of the resident flora (37-41).  
Therapeutic treatments of IBD include the administration of broad spectrum antibiotics including 
metronidazole and ciprofloxacin (42). The increase in microbial resistance to antibiotics has generated 
interest in developing alternate treatments, including probiotics (43, 44). Probiotics are beneficial bacteria 
that aid in the metablism of nutrients, breakdown long chain fatty acids to provide butyrate to maintain the 
health of the epithelium among other functions and are hypothesized to rescue disbiosis conditions 
potentially contributing to IBD development. Although much hype has been generated towards the use of 
probiotic therapies, results are inconclusive. More specifically, commensal E. coli strains have been utilized 
for probiotic therapies and have resulted in mixed reviews (45-49). In this regard, our second specific aim 
was to determine whether the increased sensitivity to DSS was a unique feature of H. bilis colonization. 
Defined flora (DF) mice were colonized with a pathogenic H. bilis or commensal E. coli for  three or 12 
weeks prior to administration of DSS. In contrast to previous H. bilis experiments, colonization of DF mice 
with E. coli did not significantly increase the susceptibility to low-dose DSS (1.5 %); however, the 
susceptibility to typhlocolitis following exposure to a higher dose of DSS (2.5 %) was markedly increased. 
Gross and histological cecal scores of colonic tissues recovered from DF mice following colonization with 
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E. coli and high dose DSS were elevated as compared to similarly colonized mice treated with low dose 
DSS. Similar to control mice, E. coli colonized mice displayed no macroscopic lesions. As with H. bilis, 
DF mice colonized with E. coli developed ASF antigen-specific CD4+ T cell proliferative responses 
following in vitro stimulation that did not require DSS exposure. The treatment of E. coli colonized mice 
with a high-dose (2.5 %) DSS resulted in the induction of ASF-antigen-specific IL-17A secretion and cecal 
mucosal expression of IL-17A-specific mRNA. These results demonstrate that introduction of a novel 
bacterial species into the resident flora can affect mucosal homeostasis even though the bacterial strain is 
low in pathogenicity. Based on the context of complex interactions, the nature of the introduced 
provocateur and its impact on the colonic mucosa (e.g., gene expression, aberrant immunity) are critical 
factors that predispose the host to the onset of IBD (Fig 2) and caution should be taken when utilizing a 
commensal organism as probiotic therapy.  
Epithelial cells are the first line of defense against microbial invaders. There are multiple 
mechanisms involved in the maintenance of tolerance to commensal bacteria including properties of the 
specific bacteria, characteristics of the epithelium, and characteristics of the immune cells in the lamina 
propria (50, 51). For example, some reports have shown that some intestinal epithelial cell lines express 
minimal amounts of TLR4 on their plasma membranes although they make detectable amounts of TLR4-
specific mRNA (52). Depending on the degree of the inflammatory trigger, both pathogenic and 
commensal organisms were shown to differentially induced susceptibility to DSS-induced colitis. In this 
regard, the third specific aim was designed to evaluate the induction of chemokines and proinflammatory 
cytokines from murine epithelial cells exposed to H. bilis or E. coli. An intestinal epithelial cell line, 
MODE-K was exposed to live or whole cell sonicates of H. bilis or E. coli. Cell viability following addition 
of the bacteria to cell culture was assessed via MTT assay and indicated that both H. bilis and E. coli were 
cytotoxic for MODE-K cells following 12 hours of cell culture (p < .05). As previously shown (48), The 
metabolic stress associated with the presence of these bacteria may induce increased uptake of commensal 
organisms, which may indicate why E. coli induces antigen-specific CD4+ T cell reactivity to the 
commensal flora (i.e., increased antigen uptake and processing). Alternately, an increase in epithelial 
apoptosis may contribute to a breach in tolerance, explaining enhanced CD4+ responses to the resident 
microbiota (50). Consistent with mild inflammation observed in DF mice colonized with H. bilis, the 
exposure of MODE-K cells to H. bilis induced increased chemokine synthesis including MIP-2, CXCL9, 
and GM-CSF relative to that induced by E. coli.  In contrast, the result of cross-talk between E. coli and the 
epithelial cells induced IL-6 expression suggesting that laminal proprial lymphocytes may be activated or 
predisposed to a IL-17 maturation pathway. Previous data (not shown) indicated that E. coli colonization of 
DF mice resulted in elevated mucosal IL-17A as early as three weeks indicating that epithelial responses 
may contribute towards the generation of IL-17 responses characterized in vivo. Results suggest that 
bacterial colonization of the mucosal epithelium provokes innate responses that contribute to the induction 
of mucosal inflammation. The differential modulation of gene expression and cytokine secretion following 
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treatment of MODE K cells with H. bilis or E. coli indicated that the acute responses may be critical to the 
development of host responses to the persistent colonization of the GI tract with bacterial provocateurs. 
Collectively, these results have demonstrated the importance of the enteric flora in the 
development of IBD in an immune competent animal. Although H. bilis colonization increased reactivity 
towards a greater number of bacterial epitopes of the resident microbiota over time, the lesions do not 
become more severe following 12 or 20 weeks post-colonization. Consistent with human IBD, flares do not 
become worse with time indicating that this multi-hit mouse model may be realistic of clinical cases. The 
discovery that a commensal E. coli was able to predispose to DSS-induced colitis indicates that scientists 
should not be trying to discover a single complex bacterial species as the sole cause of IBD. Continued 
research should be spent determining the mechanism of how the initial host-bacterial interactions contribute 
to a breach in tolerance to the resident flora, resulting in aberrant immune responses that predispose to IBD.  
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Figures 
 
Figure 1. Development of a multiple-hit model of IBD. Immune competent, defined flora C3H/HeN:Tac 
mice harboring the altered Schaedler’s flora were colonized with a novel bacterial provocateur, H. bilis. 
Three to 20 weeks after H. bilis colonization, low-dose (1.5%) dextran sulphate sodium (DSS) was 
administered in drinking water. The combinatory treatments resulted in clinical signs of colitis.  
 
 
COLITIS 
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Figure 2. A pathogenic and commensal organism differentially predispose to IBD. An immunological 
threshold must be crossed in order to develop inflammatory bowel disease (IBD). Colonization of defined 
flora mice with Helicobacter bilis followed by administration of 1.5% of dextran sulphate sodium (DSS) 
induced clinical signs of IBD. However, the same low dose of DSS does not induce disease following the 
introduction of a novel Escherichia coli commensal into the resident flora. Interestingly, E. coli is able to 
predispose the host to typhlocolitis following administration with a high dose (2.5%) DSS. These data 
indicate that depending upon the virulence attributes of a novel provocateur and the degree of the 
inflammatory trigger/stressor, the host may be rendered susceptible to IBD.  
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